BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34. [PMID: 19095497 DOI: 10.1016/s1470-2045(08)70285-7] [Cited by in Crossref: 3367] [Cited by in F6Publishing: 1770] [Article Influence: 259.0] [Reference Citation Analysis]
Number Citing Articles
1 Zheng M, Xu H, Liao XH, Chen CP, Zhang AL, Lu W, Wang L, Yang D, Wang J, Liu H, Zhou XZ, Lu KP. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. Oncotarget 2017;8:29771-84. [PMID: 28404959 DOI: 10.18632/oncotarget.15967] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
2 Bae SH, Jang WI, Park HC. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget. 2017;8:59965-59976. [PMID: 28938697 DOI: 10.18632/oncotarget.19219] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
3 Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol 2015;7:566-74. [PMID: 25848480 DOI: 10.4254/wjh.v7.i3.566] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
4 Chen J, Yu Y, Ji T, Ma R, Chen M, Li G, Li F, Ding Q, Kang Q, Huang D, Liang X, Lin H, Cai X. Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma. Cancer Med 2016;5:2678-87. [PMID: 27650414 DOI: 10.1002/cam4.788] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
5 Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes. In Vivo 2019;33:1411-20. [PMID: 31471386 DOI: 10.21873/invivo.11618] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
6 Bouattour M, Mehta N, He AR, Cohen EI, Nault JC. Systemic Treatment for Advanced Hepatocellular Carcinoma. Liver Cancer. 2019;8:341-358. [PMID: 31768344 DOI: 10.1159/000496439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 16.5] [Reference Citation Analysis]
7 Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018;67:380-388. [PMID: 29150490 DOI: 10.1136/gutjnl-2017-315068] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 20.5] [Reference Citation Analysis]
8 Yu X, Ge N, Guo X, Shen S, Liang J, Huang X, Wan S, Xing J, Huang Q, Yang Y. Genetic variants in the EPCAM gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma with portal vein tumor thrombus. PLoS One 2014;9:e93416. [PMID: 24718422 DOI: 10.1371/journal.pone.0093416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
9 Yeh HW, Lee SS, Chang CY, Hu CM, Jou YS. Pyrimidine metabolic rate limiting enzymes in poorly-differentiated hepatocellular carcinoma are signature genes of cancer stemness and associated with poor prognosis. Oncotarget 2017;8:77734-51. [PMID: 29100421 DOI: 10.18632/oncotarget.20774] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
10 Lee SU, Park JW, Kim TH, Kim YJ, Woo SM, Koh YH, Lee WJ, Park SJ, Kim DY, Kim CM. Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol. 2014;190:806-814. [PMID: 24589917 DOI: 10.1007/s00066-014-0604-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 7.1] [Reference Citation Analysis]
11 Li L, Yeo W. Value of quality of life analysis in liver cancer: A clinician's perspective. World J Hepatol. 2017;9:867-883. [PMID: 28804570 DOI: 10.4254/wjh.v9.i20.867] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
12 Chen KH, Weng MT, Chou YH, Lu YF, Hsieh CH. Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report. Medicine (Baltimore) 2016;95:e3133. [PMID: 26986168 DOI: 10.1097/MD.0000000000003133] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
13 Li M, Lin S, Wilson L, Huang P, Wang H, Lai S, Dong L, Xu X, Weng X. Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion. Front Oncol 2021;11:562135. [PMID: 33767976 DOI: 10.3389/fonc.2021.562135] [Reference Citation Analysis]
14 Ma L, Chua MS, Andrisani O, So S. Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol 2014;20:333-45. [PMID: 24574704 DOI: 10.3748/wjg.v20.i2.333] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
15 Hashiba T, Yamashita T, Okada H, Nio K, Hayashi T, Asahina Y, Hayashi T, Terashima T, Iida N, Takatori H, Shimakami T, Kawaguchi K, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Takamura H, Ohta T, Honda M, Kaneko S. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol 2020;10:269-85. [PMID: 32169577 DOI: 10.1016/j.jcmgh.2020.02.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
16 Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study. Mol Clin Oncol 2017;7:1013-20. [PMID: 29285366 DOI: 10.3892/mco.2017.1442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lee JI, Kim JK, Kim DY, Ahn SH, Park JY, Kim SU, Kim BK, Han KH, Lee KS. Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. Clin Exp Metastasis. 2014;31:475-482. [PMID: 24496959 DOI: 10.1007/s10585-014-9641-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
18 Aoki T, Kudo M, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M, Nishida N. Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. Cancers (Basel) 2020;12:E3048. [PMID: 33092011 DOI: 10.3390/cancers12103048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
19 Rimassa L, Abbadessa G, Personeni N, Porta C, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, De Toni EN, Weiss A, Miles S, Gasbarrini A, Lencioni M, Lamar ME, Wang Y, Shuster D, Schwartz BE, Santoro A. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget. 2016;7:72622-72633. [PMID: 27579536 DOI: 10.18632/oncotarget.11621] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 13.7] [Reference Citation Analysis]
20 Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L, Genco C, Midiri M, Lagalla R, Brancatelli G. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. Radiol med 2014;119:215-21. [DOI: 10.1007/s11547-013-0332-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
21 Lee M, Jeon JY, Neugent ML, Kim JW, Yun M. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. Clin Exp Metastasis. 2017;34:251-260. [PMID: 28429188 DOI: 10.1007/s10585-017-9847-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
22 Chen MY, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Tsang NM, Chan KM, Lee WC. Efficacy of External Beam Radiation-Based Treatment plus Locoregional Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis. Biomed Res Int 2016;2016:6017406. [PMID: 27999803 DOI: 10.1155/2016/6017406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
23 Burak KW, Kneteman NM. An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol 2010;24:643-50. [PMID: 21157578 DOI: 10.1155/2010/410574] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
24 Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51-69. [PMID: 26020029 DOI: 10.1159/000367728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
25 Shomura M, Okabe H, Sato E, Fukai K, Shiraishi K, Hirose S, Tsuruya K, Arase Y, Anzai K, Kagawa T. Hypothyroidism is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy. Cancers (Basel) 2020;12:E3078. [PMID: 33105621 DOI: 10.3390/cancers12113078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
26 Que J, Kuo HT, Lin LC, Lin KL, Lin CH, Lin YW, Yang CC. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma. BMC Cancer 2016;16:451. [PMID: 27405814 DOI: 10.1186/s12885-016-2512-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
27 Liu C, Wu H, Mao Y, Chen W, Chen S. Exosomal microRNAs in hepatocellular carcinoma. Cancer Cell Int 2021;21:254. [PMID: 33964930 DOI: 10.1186/s12935-021-01941-9] [Reference Citation Analysis]
28 Li W, Wang Y, Kellner DB, Zhao L, Xu L, Gao Q. Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma. Oncol Lett. 2016;12:707-714. [PMID: 27347204 DOI: 10.3892/ol.2016.4629] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
29 Zou ZM, Chang DH, Liu H, Xiao YD. Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know? Insights Imaging 2021;12:31. [PMID: 33675433 DOI: 10.1186/s13244-021-00977-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Feng D, Hui X, Shi-Chun L, Yan-Hua B, Li C, Xiao-Hui L, Jie-Yu Y. Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma. Oncotarget 2017;8:96649-55. [PMID: 29228559 DOI: 10.18632/oncotarget.20029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
31 Zhong J, Xiang B, Ma L, Li L. Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma: A systematic review. Mol Clin Oncol 2014;2:1091-6. [PMID: 25279203 DOI: 10.3892/mco.2014.337] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
32 Hung MH, Tai WT, Shiau CW, Chen KF. Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. World J Gastroenterol. 2014;20:15269-15274. [PMID: 25386075 DOI: 10.3748/wjg.v20.i41.15269] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
33 Xiao Y, Sun L, Fu Y, Huang Y, Zhou R, Hu X, Zhou P, Quan J, Li N, Fan XG. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo. BMC Cancer. 2017;17:857. [PMID: 29246127 DOI: 10.1186/s12885-017-3868-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
34 Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol. 2014;20:235-241. [PMID: 24415877 DOI: 10.3748/wjg.v20.i1.235] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
35 Zhang EL, Zhang ZY, Li J, Huang ZY. Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient. Onco Targets Ther 2020;13:12477-87. [PMID: 33311988 DOI: 10.2147/OTT.S284092] [Reference Citation Analysis]
36 Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, Sata M. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol 2013;6:511-9. [PMID: 24151531 DOI: 10.1593/tlo.13481] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
37 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Reference Citation Analysis]
38 Chiang CL, Chan MKH, Yeung CSY, Ho CHM, Lee FAS, Lee VWY, Wong FCS, Blanck O. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma. Strahlenther Onkol 2019;195:254-64. [PMID: 30413833 DOI: 10.1007/s00066-018-1391-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
39 Oh MJ, Lee HJ, Lee SH. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. Clin Mol Hepatol. 2013;19:288-299. [PMID: 24133667 DOI: 10.3350/cmh.2013.19.3.288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
40 Mußbach F, Ungefroren H, Günther B, Katenkamp K, Henklein P, Westermann M, Settmacher U, Lenk L, Sebens S, Müller JP, Böhmer FD, Kaufmann R. Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo. Mol Cancer 2016;15:54. [PMID: 27473374 DOI: 10.1186/s12943-016-0538-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
41 Aitcheson G, Pillai A, Dahman B, John BV. Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma. Curr Hepatol Rep 2021;:1-11. [PMID: 33552839 DOI: 10.1007/s11901-021-00560-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Kim JO, Kim KH, Song IS, Cheon KS, Kim OH, Lee SC, Lee SK, Kim SJ. Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells. Oncotarget 2017;8:2936-48. [PMID: 27935857 DOI: 10.18632/oncotarget.13808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
43 Reiss KA, Yu S, Mamtani R, Mehta R, D'Addeo K, Wileyto EP, Taddei TH, Kaplan DE. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. J Clin Oncol 2017;35:3575-81. [PMID: 28872925 DOI: 10.1200/JCO.2017.73.8245] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
44 Takahashi A, Yamamoto Y, Yasunaga M, Koga Y, Kuroda J, Takigahira M, Harada M, Saito H, Hayashi T, Kato Y, Kinoshita T, Ohkohchi N, Hyodo I, Matsumura Y. NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci 2013;104:920-5. [PMID: 23495762 DOI: 10.1111/cas.12153] [Cited by in Crossref: 82] [Cited by in F6Publishing: 58] [Article Influence: 10.3] [Reference Citation Analysis]
45 Li X, Wan J, Wu Z, Tu J, Hu Y, Wu S, Lou L. Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2018;12:3043-9. [PMID: 30271119 DOI: 10.2147/DDDT.S151241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Hou T, Wang T, Mu W, Yang R, Liang S, Zhang Z, Fu S, Gao T, Liu Y, Zhang N. Nanoparticle-Loaded Polarized-Macrophages for Enhanced Tumor Targeting and Cell-Chemotherapy. Nanomicro Lett 2020;13:6. [PMID: 34138195 DOI: 10.1007/s40820-020-00531-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Nomura T, Tani J, Deguchi A, Nakahara M, Oura K, Tadokoro T, Fujita K, Mimura S, Sakamoto T, Morishita A, Yoneyama H, Kobara H, Sanomura T, Nishiyama Y, Okano K, Suzuki Y, Takahashi S, Shibata T, Tsutsui K, Himoto T, Masaki T. Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion. Mol Clin Oncol 2019;11:447-54. [PMID: 31602300 DOI: 10.3892/mco.2019.1920] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Chen BB, Shih TT. DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. World J Gastroenterol 2014;20:3125-34. [PMID: 24695624 DOI: 10.3748/wjg.v20.i12.3125] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
49 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
50 Zhu XD, Tang ZY, Sun HC. Targeting angiogenesis for liver cancer: Past, present, and future. Genes Dis 2020;7:328-35. [PMID: 32884987 DOI: 10.1016/j.gendis.2020.03.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
51 Sekino Y, Okumura T, Fukumitsu N, Iizumi T, Numajiri H, Mizumoto M, Nakai K, Nonaka T, Ishikawa H, Sakurai H. Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Cancer Res Clin Oncol 2020;146:711-20. [PMID: 31776663 DOI: 10.1007/s00432-019-03096-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
52 Rodríguez-Hernández MA, Chapresto-Garzón R, Cadenas M, Navarro-Villarán E, Negrete M, Gómez-Bravo MA, Victor VM, Padillo FJ, Muntané J. Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells. Cell Death Dis 2020;11:339. [PMID: 32382022 DOI: 10.1038/s41419-020-2558-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
53 Kim JH, Ahn DH, Moon JS, Han HJ, Bae K, Yoon KA. Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib). Vet Q 2021;41:153-62. [PMID: 33764261 DOI: 10.1080/01652176.2021.1905194] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Pocha PV, Xie C, Pocha C. Addition of apatinib to transarterial chemoembolization leads to improved outcome in patients with intermediate and advanced hepatocellular cancer. Ann Transl Med 2021;9:2. [PMID: 33553295 DOI: 10.21037/atm-20-7534] [Reference Citation Analysis]
55 Ko KL, Mak LY, Cheung KS, Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Res 2020;9:F1000 Faculty Rev-620. [PMID: 32595940 DOI: 10.12688/f1000research.24543.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
56 Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. BMC Res Notes 2015;8:609. [PMID: 26502722 DOI: 10.1186/s13104-015-1565-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
57 Min X, Wen J, Zhao L, Wang K, Li Q, Huang G, Liu J, Zhao X. Role of hepatoma-derived growth factor in promoting de novo lipogenesis and tumorigenesis in hepatocellular carcinoma. Mol Oncol 2018;12:1480-97. [PMID: 30004626 DOI: 10.1002/1878-0261.12357] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
58 Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol. 2017;52:494-503. [PMID: 27549242 DOI: 10.1007/s00535-016-1247-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
59 Mei J, Li SH, Li QJ, Sun XQ, Lu LH, Lin WP, Zheng L, Chen MS, Shi M, Wei W, Guo RP. Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:167-76. [PMID: 33791252 DOI: 10.2147/JHC.S298538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Liu B, Huang JW, Li Y, Hu BS, He X, Zhao W, Zheng YB, Lu LG. Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial. J Cancer Res Clin Oncol 2015;141:1103-8. [PMID: 25504506 DOI: 10.1007/s00432-014-1866-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
61 Kim TS, Kim JH, Kim BH, Lee YS, Yoo YJ, Kang SH, Suh SJ, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS. Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review. Clin Mol Hepatol 2017;23:340-6. [PMID: 28633200 DOI: 10.3350/cmh.2016.0070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
62 Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012;17:359-366. [PMID: 22334456 DOI: 10.1634/theoncologist.2011-0313] [Cited by in Crossref: 105] [Cited by in F6Publishing: 108] [Article Influence: 11.7] [Reference Citation Analysis]
63 Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Honda M, Kaneko S, Sato T, Sato S, Obi S, Iwadou S, Kobayashi Y, Takaguchi K, Kariyama K, Takuma Y, Takabatake H, Yamamoto K;  Okayama Liver Cancer Group. Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. Br J Cancer. 2013;109:2072-2078. [PMID: 24045661 DOI: 10.1038/bjc.2013.554] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
64 Liu HZ, Deng W, Li JL, Tang YM, Zhang LT, Cui Y, Liang XQ. Peripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma. Oncotarget 2016;7:77558-64. [PMID: 27813499 DOI: 10.18632/oncotarget.13041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
65 Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A, Hoppe-Lotichius M, Koch S, Schad A, Schattenberg JM, Wörns MA, Weinmann A, Galle PR, Zimmermann T. Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer 2016;16:94. [PMID: 26872727 DOI: 10.1186/s12885-016-2150-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
66 Kudo M. Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives. Liver Cancer. 2017;6:101-112. [PMID: 28275577 DOI: 10.1159/000452138] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
67 Lee D, Xu IM, Chiu DK, Lai RK, Tse AP, Lan Li L, Law CT, Tsang FH, Wei LL, Chan CY, Wong CM, Ng IO, Wong CC. Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. J Clin Invest 2017;127:1856-72. [PMID: 28394261 DOI: 10.1172/JCI90253] [Cited by in Crossref: 50] [Cited by in F6Publishing: 34] [Article Influence: 12.5] [Reference Citation Analysis]
68 Quencer KB, Friedman T, Sheth R, Oklu R. Tumor thrombus: incidence, imaging, prognosis and treatment. Cardiovasc Diagn Ther 2017;7:S165-77. [PMID: 29399520 DOI: 10.21037/cdt.2017.09.16] [Cited by in Crossref: 50] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
69 Sacco R, Conte C, Tumino E, Parisi G, Marceglia S, Metrangolo S, Eggenhoffner R, Bresci G, Cabibbo G, Giacomelli L. Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016;3:25-9. [PMID: 27574589 DOI: 10.2147/JHC.S50359] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
70 Salem ME, Jain N, Dyson G, Taylor S, El-Refai SM, Choi M, Shields AF, Critchfield J, Philip PA. Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization. ISRN Oncol 2013;2013:538376. [PMID: 24167742 DOI: 10.1155/2013/538376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Kondo M, Morimoto M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Aikata H, Hatanaka T, Takizawa D, Matsunaga K, Okuse C, Suzuki M, Taguri M, Ishibashi T, Numata K, Maeda S, Tanaka K. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer 2019;19:954. [PMID: 31615466 DOI: 10.1186/s12885-019-6198-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
72 Al-Rajabi R, Patel S, Ketchum NS, Jaime NA, Lu TW, Pollock BH, Mahalingam D. Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction. J Gastrointest Oncol. 2015;6:259-267. [PMID: 26029452 DOI: 10.3978/j.issn.2078-6891.2015.005] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
73 Faloppi L, Scartozzi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, Del Prete M, De Minicis S, Bitetto D, Loretelli C. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer. 2014;14:110. [PMID: 24552144 DOI: 10.1186/1471-2407-14-110] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
74 Xia H, Lee KW, Chen J, Kong SN, Sekar K, Deivasigamani A, Seshachalam VP, Goh BKP, Ooi LL, Hui KM. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. Cell Death Discov 2017;3:17058. [PMID: 28900541 DOI: 10.1038/cddiscovery.2017.58] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
75 Kuppusamy P, Nagalingam A, Muniraj N, Saxena NK, Sharma D. Concomitant activation of ETS-like transcription factor-1 and Death Receptor-5 via extracellular signal-regulated kinase in withaferin A-mediated inhibition of hepatocarcinogenesis in mice. Sci Rep 2017;7:17943. [PMID: 29263422 DOI: 10.1038/s41598-017-18190-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
76 Tse AP, Sze KM, Shea QT, Chiu EY, Tsang FH, Chiu DK, Zhang MS, Lee D, Xu IM, Chan CY, Koh HY, Wong CM, Zheng YP, Ng IO, Wong CC. Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis. 2018;7:44. [PMID: 29799025 DOI: 10.1038/s41389-018-0052-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
77 Zhang J, Zong Y, Xu GZ, Xing K. Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials. Saudi Med J 2016;37:1184-90. [PMID: 27761555 DOI: 10.15537/smj.2016.11.16267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
78 Deng T, Hu B, Jin C, Tong Y, Zhao J, Shi Z, Zhang T, Deng L, Sun Z, Chen G, Wang Y. A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma. J Cell Mol Med 2021;25:6618-33. [PMID: 34085405 DOI: 10.1111/jcmm.16666] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Wang HW, Chuang PH, Su WP, Kao JT, Hsu WF, Lin CC, Huang GT, Lin JT, Lai HC, Peng CY. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3758. [PMID: 34359658 DOI: 10.3390/cancers13153758] [Reference Citation Analysis]
80 Sanda M, Tamai H, Deguchi H, Mori Y, Moribata K, Shingaki N, Ueda K, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M. Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib. ISRN Gastroenterol 2011;2011:201529. [PMID: 21991498 DOI: 10.5402/2011/201529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
81 Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, Lan PC, Yang MH, Chang TS, Huang YH. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res 2019;38:474. [PMID: 31771617 DOI: 10.1186/s13046-019-1442-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
82 Liu TP, Lo HL, Wei LS, Hsiao HH, Yang PM. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells. Anticancer Drugs 2015;26:139-47. [PMID: 25203626 DOI: 10.1097/CAD.0000000000000166] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 6.2] [Reference Citation Analysis]
83 Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J. Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World J Gastroenterol 2017;23:2448-52. [PMID: 28428725 DOI: 10.3748/wjg.v23.i13.2448] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
84 Qin S, Gong X. Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. Hepat Oncol 2016;3:71-81. [PMID: 30191027 DOI: 10.2217/hep.15.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Barbier L, Muscari F, Le Guellec S, Pariente A, Otal P, Suc B. Liver resection after downstaging hepatocellular carcinoma with sorafenib. Int J Hepatol. 2011;2011:791013. [PMID: 22135750 DOI: 10.4061/2011/791013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
86 Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis. PLoS One 2018;13:e0207132. [PMID: 30408106 DOI: 10.1371/journal.pone.0207132] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
87 Ying ZL, Li XJ, Dang H, Wang F, Xu XY. Saikosaponin-d affects the differentiation, maturation and function of monocyte-derived dendritic cells. Exp Ther Med. 2014;7:1354-1358. [PMID: 24940438 DOI: 10.3892/etm] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
88 Vatsyayan R, Singhal J, Nagaprashantha LD, Awasthi S, Singhal SS. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma. Mol Carcinog 2013;52:39-48. [PMID: 22006587 DOI: 10.1002/mc.20875] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
89 Kim MS, Jin YJ, Lee JW, Lee JI, Kim YS, Lee SY, Chae MH. Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. World J Gastrointest Oncol. 2013;5:38-42. [PMID: 23556056 DOI: 10.4251/wjgo.v5.i2.38] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
90 Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci. 2014;59:1688-1697. [PMID: 24573715 DOI: 10.1007/s10620-014-3058-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
91 Watari K, Nishitani A, Shibata T, Noda M, Kawahara A, Akiba J, Murakami Y, Yano H, Kuwano M, Ono M. Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma. Oncotarget 2016;7:47403-17. [PMID: 27329724 DOI: 10.18632/oncotarget.10161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
92 Liao LZ, Chen CT, Li NC, Lin LC, Huang BS, Chang YH, Chow LP. Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells. Int J Mol Sci 2020;22:E224. [PMID: 33379356 DOI: 10.3390/ijms22010224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
93 Asmis T, Balaa F, Scully L, Papadatos D, Marginean C, Fasih N, Shaw-Stiffel T, Goel R. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol 2010;17:6-12. [PMID: 20404972 DOI: 10.3747/co.v17i2.555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
94 Alshahrani AA, Hwang S, Song GW, Moon DB, Jung DH, Ahn CS, Kim KH, Ha TY, Park GC, Ha SM, Park YH, Lee SG. Management of very late peritoneal metastasis of hepatocellular carcinoma 10 years after liver transplantation: Lessons from two cases. Ann Hepatobiliary Pancreat Surg 2018;22:136-43. [PMID: 29896574 DOI: 10.14701/ahbps.2018.22.2.136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
95 Ye J, Qi L, Liang J, Zong K, Liu W, Li R, Feng R, Zhai W. Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT. J Cancer 2021;12:3548-57. [PMID: 33995632 DOI: 10.7150/jca.50292] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Li WF, Ou Q, Dai H, Liu CA. Lentiviral-Mediated Short Hairpin RNA Knockdown of MTDH Inhibits Cell Growth and Induces Apoptosis by Regulating the PTEN/AKT Pathway in Hepatocellular Carcinoma. Int J Mol Sci 2015;16:19419-32. [PMID: 26287185 DOI: 10.3390/ijms160819419] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
97 Li C, Xu X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. Cell Mol Life Sci 2019;76:4203-19. [PMID: 31300868 DOI: 10.1007/s00018-019-03215-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
98 Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 2013;119:3334-42. [PMID: 23821538 DOI: 10.1002/cncr.28209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
99 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 101] [Article Influence: 11.7] [Reference Citation Analysis]
100 Kim H, Yu SJ, Yeo I, Cho YY, Lee DH, Cho Y, Cho EJ, Lee JH, Kim YJ, Lee S, Jun J, Park T, Yoon JH, Kim Y. Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). Mol Cell Proteomics 2017;16:1312-23. [PMID: 28550167 DOI: 10.1074/mcp.M116.066704] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 3.8] [Reference Citation Analysis]
101 Lee JJX, Chan JJ, Choo SP. Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma. Diseases 2015;3:306-24. [PMID: 28943627 DOI: 10.3390/diseases3040306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
102 Brar G, Greten TF, Brown ZJ. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Therap Adv Gastroenterol 2018;11:1756284818808086. [PMID: 30377451 DOI: 10.1177/1756284818808086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
103 Kajihara J, Tomimaru Y, Eguchi H, Yamada D, Wada H, Tomokuni A, Asaoka T, Kawamoto K, Marubashi S, Nagano H, Umeshita K, Doki Y, Mori M. The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma. Dig Dis Sci 2016;61:1572-81. [PMID: 26725068 DOI: 10.1007/s10620-015-4018-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
104 Weledji EP, Enow Orock G, Ngowe MN, Nsagha DS. How grim is hepatocellular carcinoma? Ann Med Surg (Lond) 2014;3:71-6. [PMID: 25568791 DOI: 10.1016/j.amsu.2014.06.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
105 She WH, Cheung TT. Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl Gastroenterol Hepatol. 2016;1:34. [PMID: 28138601 DOI: 10.21037/tgh.2016.03.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
106 Amicone L, Marchetti A. Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. Transl Gastroenterol Hepatol 2018;3:24. [PMID: 29971255 DOI: 10.21037/tgh.2018.04.05] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
107 Zeng J, Wang C, Wang Y, Luo Z, Zhang Y, Luo X. Sorafenib plus partial splenic embolism for treatment of hepatocellular carcinoma Barcelona stage C combined with hypersplenism: a case series. J Int Med Res 2021;49:3000605211023351. [PMID: 34139869 DOI: 10.1177/03000605211023351] [Reference Citation Analysis]
108 Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol 2020;38:2960-70. [PMID: 32716739 DOI: 10.1200/JCO.20.00808] [Cited by in Crossref: 100] [Cited by in F6Publishing: 70] [Article Influence: 100.0] [Reference Citation Analysis]
109 Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Oncologist 2016;21:1113-20. [PMID: 27185615 DOI: 10.1634/theoncologist.2015-0478] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 12.8] [Reference Citation Analysis]
110 Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G. Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Ther Clin Risk Manag 2015;11:1603-12. [PMID: 26527877 DOI: 10.2147/TCRM.S88208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
111 Pan Y, Hu GY, Jiang S, Xia SJ, Maher H, Lin ZJ, Mao QJ, Zhao J, Cai LX, Xu YH, Xu JJ, Cai XJ. Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma. Front Oncol 2021;11:637971. [PMID: 34094917 DOI: 10.3389/fonc.2021.637971] [Reference Citation Analysis]
112 Collettini F, Schnapauff D, Poellinger A, Denecke T, Schott E, Berg T, Wust P, Hamm B, Gebauer B. Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (>7 cm) tumours. Eur Radiol 2012;22:1101-9. [PMID: 22173693 DOI: 10.1007/s00330-011-2352-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
113 Lee S, Kim JH, Moon H, Lee HJ, Han JK. Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study. PLoS One 2020;15:e0243815. [PMID: 33306731 DOI: 10.1371/journal.pone.0243815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
114 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
115 Naganuma A, Hoshino T, Ohno N, Ogawa Y, Murakami T, Horiguchi S, Uehara D, Suzuki Y, Hatanaka T, Kudo T, Ishihara H, Sato K, Kakizaki S, Takagi H. β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma. In Vivo 2019;33:155-61. [PMID: 30587616 DOI: 10.21873/invivo.11452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
116 Sohn BH, Park IY, Shin JH, Yim SY, Lee JS. Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells. Exp Mol Med 2018;50:e421. [PMID: 29303508 DOI: 10.1038/emm.2017.174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
117 Zeng Z, Lu Q, Liu Y, Zhao J, Zhang Q, Hu L, Shi Z, Tu Y, Xiao Z, Xu Q, Huang D. Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma. Front Oncol 2021;11:641522. [PMID: 34307125 DOI: 10.3389/fonc.2021.641522] [Reference Citation Analysis]
118 Hayashi T, Yamashita T, Terashima T, Suda T, Okada H, Asahina Y, Hayashi T, Hara Y, Nio K, Sunagozaka H. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. BMC Cancer. 2017;17:870. [PMID: 29258450 DOI: 10.1186/s12885-017-3889-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
119 Feng D, Wang M, Hu J, Li S, Zhao S, Li H, Liu L. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med 2020;8:553. [PMID: 32411776 DOI: 10.21037/atm.2020.02.116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
120 Hu B, Cheng JW, Hu JW, Li H, Ma XL, Tang WG, Sun YF, Guo W, Huang A, Zhou KQ, Gao PT, Cao Y, Qiu SJ, Zhou J, Fan J, Yang XR. KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. J Cancer 2019;10:3914-25. [PMID: 31417635 DOI: 10.7150/jca.31448] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
121 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21:3462-3471. [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
122 Amaro CP, Tam VC. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond. Curr Oncol 2020;27:S173-80. [PMID: 33343211 DOI: 10.3747/co.27.7103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 López-Grueso MJ, González R, Muntané J, Bárcena JA, Padilla CA. Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells. Antioxidants (Basel) 2019;8:E501. [PMID: 31652503 DOI: 10.3390/antiox8100501] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
124 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. [PMID: 21374666 DOI: 10.1002/hep.24199.] [Reference Citation Analysis]
125 Shin IS, Rim CH. Stepwise-Hierarchical Pooled Analysis for Synergistic Interpretation of Meta-analyses Involving Randomized and Observational Studies: Methodology Development. J Med Internet Res 2021;23:e29642. [PMID: 34315697 DOI: 10.2196/29642] [Reference Citation Analysis]
126 Yao W, Ba Q, Li X, Li H, Zhang S, Yuan Y, Wang F, Duan X, Li J, Zhang W, Wang H. A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer. EBioMedicine 2017;22:58-67. [PMID: 28754304 DOI: 10.1016/j.ebiom.2017.07.014] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
127 Jiang SS, Tang Y, Zhang YJ, Weng DS, Zhou ZG, Pan K, Pan QZ, Wang QJ, Liu Q, He J, Zhao JJ, Li J, Chen MS, Chang AE, Li Q, Xia JC. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget. 2015;6:41339-41349. [PMID: 26515587 DOI: 10.18632/oncotarget.5463] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
128 Ahn SJ, Park MS, Kim KA, Park JY, Kim I, Kang WJ, Lee SK, Kim MJ. 18F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study. PLoS One. 2013;8:e71571. [PMID: 23940769 DOI: 10.1371/journal.pone.0071571] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
129 Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S. Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. Br J Cancer 2021;125:190-9. [PMID: 33824476 DOI: 10.1038/s41416-021-01334-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
130 Cao J, Ji D, Chen Z, Shen W, Wang J, Li B, Chi H, Long A, Gao L, Li J. Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors. Oncologist 2017;22:638-e56. [PMID: 28465370 DOI: 10.1634/theoncologist.2017-0137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
131 Fujiki M, Aucejo F, Choi M, Kim R. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand? World J Gastroenterol. 2014;20:5308-5319. [PMID: 24833861 DOI: 10.3748/wjg.v20.i18.5308] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
132 Zhang X, Wang F, Gu G, Wu Q. High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients. J Oncol 2021;2021:9938207. [PMID: 34194500 DOI: 10.1155/2021/9938207] [Reference Citation Analysis]
133 Afshar M, Fletcher P, Bardoli AD, Ma YT, Punia P. Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort. Oncotarget 2018;9:16988-95. [PMID: 29682199 DOI: 10.18632/oncotarget.24769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
134 Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib. J Exp Clin Cancer Res 2019;38:232. [PMID: 31151472 DOI: 10.1186/s13046-019-1216-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
135 Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer 2010;103:837-44. [PMID: 20717115 DOI: 10.1038/sj.bjc.6605858] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
136 Yokoo H, Takahashi H, Hagiwara M, Iwata H, Imai K, Saito Y, Matsuno N, Furukawa H. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report. World J Hepatol 2020;12:1349-57. [PMID: 33442460 DOI: 10.4254/wjh.v12.i12.1349] [Reference Citation Analysis]
137 Finn RS. Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer 2012;1:247-56. [PMID: 24159589 DOI: 10.1159/000343839] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
138 Zhang X, Wang J, Shi J, Jia X, Dang S, Wang W. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma. JAMA Netw Open 2021;4:e214846. [PMID: 33825837 DOI: 10.1001/jamanetworkopen.2021.4846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
139 Khorsandi SE, Heaton N. Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence. Transl Gastroenterol Hepatol 2016;1:25. [PMID: 28138592 DOI: 10.21037/tgh.2016.03.18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
140 Chu SS, Kuo YH, Liu WS, Wang SC, Ho CH, Chen YC, Yang CC, Wu HC. Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study. Sci Rep 2021;11:1614. [PMID: 33452421 DOI: 10.1038/s41598-021-81176-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
141 Shao YY, Li YS, Hsu HW, Lin H, Wang HY, Wo RR, Cheng AL, Hsu CH. Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1433. [PMID: 31561409 DOI: 10.3390/cancers11101433] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
142 Liu B, Ding F, Liu Y, Xiong G, Lin T, He D, Zhang Y, Zhang D, Wei G. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 2016;7:67661-73. [PMID: 27602778 DOI: 10.18632/oncotarget.11813] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
143 Yamamoto N, Yamasaki T, Takami T, Uchida K, Fujisawa K, Matsumoto T, Saeki I, Terai S, Sakaida I. Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib. J Clin Biochem Nutr. 2016;58:202-209. [PMID: 27257345 DOI: 10.3164/jcbn.15-127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
144 Cheng TY, Lee PC, Chen YT, Chao Y, Hou MC, Huang YH. Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure. Sci Rep 2020;10:18375. [PMID: 33110117 DOI: 10.1038/s41598-020-75198-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
145 Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci. 2014;15:10578-10604. [PMID: 24927147 DOI: 10.3390/ijms150610578] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
146 Gou M, Si H, Zhang Y, Qian N, Wang Z, Shi W, Dai G. Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. Sci Rep. 2018;8:4602. [PMID: 29545575 DOI: 10.1038/s41598-018-22302-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
147 Liu L, Zhang Q, Geng J, Li S, Zhao S, Zhang X, Hu J, Feng D. Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates. Ann Transl Med 2020;8:583. [PMID: 32566610 DOI: 10.21037/atm.2020.03.71] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Cammarota A, D'Alessio A, Pressiani T, Rimassa L, Personeni N. Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs Aging 2021;38:579-91. [PMID: 34152589 DOI: 10.1007/s40266-021-00871-5] [Reference Citation Analysis]
149 Shimizu D, Kanda M, Sugimoto H, Shibata M, Tanaka H, Takami H, Iwata N, Hayashi M, Tanaka C, Kobayashi D, Yamada S, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. Int J Oncol 2017;50:381-6. [PMID: 28101581 DOI: 10.3892/ijo.2017.3833] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
150 Nishikawa H, Takeda H, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Osaki Y, Izumi N; Japanese Red Cross Liver Study Group. Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan. J Cancer 2014;5:499-509. [PMID: 24963354 DOI: 10.7150/jca.9257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
151 Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer Med 2019;8:3719-28. [PMID: 31127698 DOI: 10.1002/cam4.2241] [Cited by in Crossref: 39] [Cited by in F6Publishing: 48] [Article Influence: 19.5] [Reference Citation Analysis]
152 Yang M, Yuan JQ, Bai M, Han GH. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Mol Biol Rep. 2014;41:6575-6582. [PMID: 25091939 DOI: 10.1007/s11033-014-3541-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
153 Guan J, Yang Q, Chen C, Wang G, Zhu H. Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis. EXCLI J 2021;20:1-16. [PMID: 33510588 DOI: 10.17179/excli2020-3111] [Reference Citation Analysis]
154 Kato H, Yoshida H, Taniguch H, Nomura R, Sato K, Suzuki I, Nakata R. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol 2015;21:13101-12. [PMID: 26673627 DOI: 10.3748/wjg.v21.i46.13101] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
155 Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol. 2015;21:10314-10326. [PMID: 26420958 DOI: 10.3748/wjg.v21.i36.10314] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
156 Chen ATC, Payão F, Chagas AL, De Souza Melo Alencar RS, Tani CM, da Conceição Vasconcelos KGM, de Souza Rocha M, de Andrade Carvalho H, Hoff PMG, Carrilho FJ. Feasibility of SBRT for hepatocellular carcinoma in Brazil - a prospective pilot study. Rep Pract Oncol Radiother 2021;26:226-36. [PMID: 34211773 DOI: 10.5603/RPOR.a2021.0035] [Reference Citation Analysis]
157 Yao X, Yan D, Liu D, Zeng H, Li H. Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma. Mol Clin Oncol 2015;3:929-35. [PMID: 26171209 DOI: 10.3892/mco.2015.554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
158 Wang J, Chen X, Tian Y, Zhu G, Qin Y, Chen X, Pi L, Wei M, Liu G, Li Z, Chen C, Lv Y, Cai G. Six-gene signature for predicting survival in patients with head and neck squamous cell carcinoma. Aging (Albany NY) 2020;12:767-83. [PMID: 31927533 DOI: 10.18632/aging.102655] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
159 da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol. 2014;31:264. [PMID: 25273866 DOI: 10.1007/s12032-014-0264-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
160 Ren B, Wang W, Shen J, Li W, Ni C, Zhu X. Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study. J Cancer 2019;10:1189-96. [PMID: 30854128 DOI: 10.7150/jca.28994] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
161 Tovoli F, Negrini G, Benevento F, Faggiano C, Goio E, Granito A. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepat Oncol 2018;5:HEP01. [PMID: 30302192 DOI: 10.2217/hep-2017-0020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
162 Hiramine Y, Uto H, Imamura Y, Tabu K, Baba Y, Hiwaki T, Sho Y, Tahara K, Higashi H, Tamai T. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med. 2011;2:433-441. [PMID: 22977522 DOI: 10.3892/etm.2011.237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
163 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
164 Liao Y, Zheng Y, He W, Li Q, Shen J, Hong J, Zou R, Qiu J, Li B, Yuan Y. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncol Lett 2017;13:984-92. [PMID: 28356989 DOI: 10.3892/ol.2016.5525] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
165 El Dika I, Makki I, Abou-Alfa GK. Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin Oncol 2021;10:12. [PMID: 32527116 DOI: 10.21037/cco-20-113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
166 Wang H, Rao B, Lou J, Li J, Liu Z, Li A, Cui G, Ren Z, Yu Z. The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. Front Cell Dev Biol 2020;8:55. [PMID: 32117981 DOI: 10.3389/fcell.2020.00055] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 24.0] [Reference Citation Analysis]
167 Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C, Neri LM, Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E, Ulivi P, Frassineti GL. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget. 2016;7:27988-27999. [PMID: 27058899 DOI: 10.18632/oncotarget.8569] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
168 Chauhan N, Bukovcan J, Boucher E, Cosgrove D, Edeline J, Hamilton B, Kulik L, Master F, Salem R. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Res Protoc 2018;7:e11234. [PMID: 30111528 DOI: 10.2196/11234] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
169 Li J, Zhou Y, Liu Y, Dai B, Zhang YH, Zhang PF, Shi XL. Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma. Cancer Biol Ther. 2018;1-8. [PMID: 30277836 DOI: 10.1080/15384047.2018.1480280] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
170 De Minicis S, Marzioni M, Benedetti A, Svegliati-Baroni G. New insights in hepatocellular carcinoma: from bench to bedside. Ann Transl Med 2013;1:15. [PMID: 25332959 DOI: 10.3978/j.issn.2305-5839.2013.01.06] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
171 Liu TP, Hong YH, Yang PM. In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells. Oncotarget 2017;8:86168-80. [PMID: 29156785 DOI: 10.18632/oncotarget.21030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
172 Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma 2020;7:77-89. [PMID: 32426302 DOI: 10.2147/JHC.S224471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
173 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
174 Klein J, Dawson LA, Tran TH, Adeyi O, Purdie T, Sherman M, Brade A. Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy. Curr Oncol 2014;21:e340-4. [PMID: 24764717 DOI: 10.3747/co.21.1756] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
175 He SL, Shen J, Sun XJ, Zhu XJ, Liu LM, Dong JC. Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. World J Gastroenterol. 2013;19:4552-4558. [PMID: 23901232 DOI: 10.3748/wjg.v19.i28.4552] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
176 Siegel AB, Olsen SK, Magun A, Brown RS. Sorafenib: where do we go from here? Hepatology. 2010;52:360-369. [PMID: 20578152 DOI: 10.1002/hep.23633] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
177 Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020;13:143. [PMID: 33109256 DOI: 10.1186/s13045-020-00977-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 21.0] [Reference Citation Analysis]
178 Yau T, Cheng PN, Chan P, Chan W, Chen L, Yuen J, Pang R, Fan ST, Poon RT. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs 2013;31:99-107. [PMID: 22426640 DOI: 10.1007/s10637-012-9807-9] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 7.8] [Reference Citation Analysis]
179 Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin Liver Dis 2011;15:423-41, vii-x. [PMID: 21689622 DOI: 10.1016/j.cld.2011.03.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
180 Kim HY, Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer. 2014;3:9-17. [PMID: 24804173 DOI: 10.1159/000343854] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
181 Chen J, Zhou C, Long Y, Yin X. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. Tumour Biol 2015;36:183-91. [PMID: 25217986 DOI: 10.1007/s13277-014-2608-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
182 Wang C, Jin H, Gao D, Wang L, Evers B, Xue Z, Jin G, Lieftink C, Beijersbergen RL, Qin W, Bernards R. A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma. Cell Res 2018;28:690-2. [PMID: 29507396 DOI: 10.1038/s41422-018-0020-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
183 Belum VR, Marulanda K, Ensslin C, Gorcey L, Parikh T, Wu S, Busam KJ, Gerber PA, Lacouture ME. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol 2015;26:2496-502. [PMID: 26387145 DOI: 10.1093/annonc/mdv390] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
184 Liu F, Meng Z, Shao G, Wang J, Wang Z, Yang J, Yip CS, He D. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study. Mol Biol Rep 2017;44:149-58. [PMID: 27981445 DOI: 10.1007/s11033-016-4092-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
185 Thompson SM, Callstrom MR, Knudsen BE, Anderson JL, Sutor SL, Butters KA, Kuo C, Grande JP, Roberts LR, Woodrum DA. Molecular bioluminescence imaging as a noninvasive tool for monitoring tumor growth and therapeutic response to MRI-guided laser ablation in a rat model of hepatocellular carcinoma. Invest Radiol 2013;48:413-21. [PMID: 23262791 DOI: 10.1097/RLI.0b013e31827a4a3f] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
186 Mahalingam D, Peguero J, Cen P, Arora SP, Sarantopoulos J, Rowe J, Allgood V, Tubb B, Campos L. A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma. Cancers (Basel). 2019;11:833. [PMID: 31212948 DOI: 10.3390/cancers11060833] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 15.5] [Reference Citation Analysis]
187 Takeda H, Nishijima N, Nasu A, Komekado H, Kita R, Kimura T, Kudo M, Osaki Y. Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion. Hepatol Res. 2019;49:594-599. [PMID: 30499247 DOI: 10.1111/hepr.13294] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
188 Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci. 2012;57:1122-1129. [PMID: 22451120 DOI: 10.1007/s10620-012-2136-1] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 8.8] [Reference Citation Analysis]
189 D'Alessandro R, Refolo MG, Lippolis C, Messa C, Cavallini A, Rossi R, Resta L, Di Carlo A, Carr BI. Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol 2013;72:869-77. [PMID: 23959464 DOI: 10.1007/s00280-013-2269-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
190 Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, Motoyama T, Ogasawara S, Suzuki E, Ooka Y. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One. 2013;8:e70010. [PMID: 23922888 DOI: 10.1371/journal.pone.0070010] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
191 Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2016;22:6851-6863. [PMID: 27570422 DOI: 10.3748/wjg.v22.i30.6851] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
192 Hong WF, Gu YJ, Wang N, Xia J, Zhou HY, Zhan K, Cheng MX, Cai Y. Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:301-14. [PMID: 34221916 DOI: 10.14218/JCTH.2020.00132] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Gbolahan OB, Schacht MA, Beckley EW, LaRoche TP, O'Neil BH, Pyko M. Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol. 2017;8:215-228. [PMID: 28480062 DOI: 10.21037/jgo.2017.03.13] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 9.5] [Reference Citation Analysis]
194 Kuorda H, Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. World J Gastroenterol. 2019;25:2365-2372. [PMID: 31148907 DOI: 10.3748/wjg.v25.i19.2365] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
195 Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group Of Japan. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Oncotarget 2016;7:64400-9. [PMID: 27462865 DOI: 10.18632/oncotarget.10794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
196 Combs SE, Habermehl D, Ganten T, Schmidt J, Edler L, Burkholder I, Jäkel O, Haberer T, Debus J. Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer. 2011;11:67. [PMID: 21314962 DOI: 10.1186/1471-2407-11-67] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
197 Gao X, Chen H, Huang X, Li H, Liu Z, Bo X. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. Onco Targets Ther 2019;12:1629-40. [PMID: 30881018 DOI: 10.2147/OTT.S196713] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
198 Kim HY, Kim CW. Ribonucleotide reductase subunit M2 can be new molecular target and prognostic biomarker of hepatocellular carcinoma. Gut Liver 2014;8:580-1. [PMID: 25368743 DOI: 10.5009/gnl14377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
199 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-11012-10233-11910] [Reference Citation Analysis]
200 Yoon HI, Song KJ, Lee IJ, Kim do Y, Han KH, Seong J. Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Cancer Res Treat. 2016;48:190-197. [PMID: 25761480 DOI: 10.4143/crt.2014.276] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
201 Kong J, Zhang Q, Liang X, Sun W. FOXK2 downregulation suppresses EMT in hepatocellular carcinoma. Open Med (Wars) 2020;15:702-8. [PMID: 33313412 DOI: 10.1515/med-2020-0129] [Reference Citation Analysis]
202 Gadaleta-Caldarola G, Infusino S, Galise I, Ranieri G, Vinciarelli G, Fazio V, Divella R, Daniele A, Filippelli G, Gadaleta CD. Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study.Oncol Lett. 2014;8:1783-1787. [PMID: 25202410 DOI: 10.3892/ol.2014.2376] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
203 Tomimaru Y, Aihara A, Wands JR, Aloman C, Kim M. A Novel Drug, CC-122, Inhibits Tumor Growth in Hepatocellular Carcinoma through Downregulation of an Oncogenic TCF-4 Isoform. Transl Oncol 2019;12:1345-56. [PMID: 31352197 DOI: 10.1016/j.tranon.2019.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
204 Nishikawa H, Osaki Y, Iguchi E, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med 2012;4:381-6. [PMID: 23181103 DOI: 10.3892/etm.2012.611] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
205 Semaan L, Zeng Q, Lu Y, Zhang Y, Zreik MM, Chamseddine MB, Chopp M, Zhang ZG, Moonka D. MicroRNA-214 enriched exosomes from human cerebral endothelial cells (hCEC) sensitize hepatocellular carcinoma to anti-cancer drugs. Oncotarget 2021;12:185-98. [PMID: 33613846 DOI: 10.18632/oncotarget.27879] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
206 Lo CH, Yang JF, Liu MY, Jen YM, Lin CS, Chao HL, Huang WY. Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy. PLoS One 2017;12:e0177793. [PMID: 28545098 DOI: 10.1371/journal.pone.0177793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
207 Lin J, Wu L, Bai X, Xie Y, Wang A, Zhang H, Yang X, Wan X, Lu X, Sang X, Zhao H. Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget 2016;7:71036-51. [PMID: 27626176 DOI: 10.18632/oncotarget.11954] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
208 von Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H. First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation. Diagnostics (Basel) 2016;6:E44. [PMID: 27916795 DOI: 10.3390/diagnostics6040044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
209 Tan W, Lin Z, Chen X, Li W, Zhu S, Wei Y, Huo L, Chen Y, Shang C. miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1. Ann Transl Med 2021;9:38. [PMID: 33553331 DOI: 10.21037/atm-20-2081] [Reference Citation Analysis]
210 Wohlleber K, Heger P, Probst P, Engel C, Diener MK, Mihaljevic AL. Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies. Qual Life Res 2021;30:2429-66. [PMID: 34283381 DOI: 10.1007/s11136-021-02810-8] [Reference Citation Analysis]
211 Yang C, Dong Z, Hong H, Dai B, Song F, Geng L, Lu J, Yang J, Sui C, Xu M. circFN1 Mediates Sorafenib Resistance of Hepatocellular Carcinoma Cells by Sponging miR-1205 and Regulating E2F1 Expression. Mol Ther Nucleic Acids 2020;22:421-33. [PMID: 33230446 DOI: 10.1016/j.omtn.2020.08.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
212 Zhu XD, Sun HC. Emerging agents and regimens for hepatocellular carcinoma. J Hematol Oncol. 2019;12:110. [PMID: 31655607 DOI: 10.1186/s13045-019-0794-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 17.5] [Reference Citation Analysis]
213 Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biol 2017;15:e2000487. [PMID: 28158308 DOI: 10.1371/journal.pbio.2000487] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 6.8] [Reference Citation Analysis]
214 Zhong W, Liu H, Deng L, Chen G, Liu Y. HBO1 overexpression is important for hepatocellular carcinoma cell growth. Cell Death Dis 2021;12:549. [PMID: 34039960 DOI: 10.1038/s41419-021-03818-1] [Reference Citation Analysis]
215 Li Z, Li M, Wang D, Hou P, Chen X, Chu S, Chai D, Zheng J, Bai J. Post-translational modifications of EZH2 in cancer. Cell Biosci 2020;10:143. [PMID: 33308321 DOI: 10.1186/s13578-020-00505-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
216 Liu Y, Lou G, Norton JT, Wang C, Kandela I, Tang S, Shank NI, Gupta P, Huang M, Avram MJ, Green R, Mazar A, Appella D, Chen Z, Huang S. 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib. FASEB J 2017;31:5453-65. [PMID: 28821631 DOI: 10.1096/fj.201700306RR] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
217 Shao GL, Zheng JP, Guo LW, Chen YT, Zeng H, Yao Z. Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study. Medicine (Baltimore) 2017;96:e5518. [PMID: 28099329 DOI: 10.1097/MD.0000000000005518] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
218 Bai T, Chen J, Xie ZB, Wu FX, Wang SD, Liu JJ, Li LQ. The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus. Onco Targets Ther. 2016;9:3841-3848. [PMID: 27390524 DOI: 10.2147/ott.s104307] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
219 Jiang H, Ning G, Wang Y, Lv W. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response. Dis Markers 2021;2021:5576683. [PMID: 34221187 DOI: 10.1155/2021/5576683] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
220 Ye DW, Zhang HL. Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma. Onco Targets Ther 2014;7:925-35. [PMID: 24944516 DOI: 10.2147/OTT.S41828] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
221 Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One 2021;16:e0249426. [PMID: 33961627 DOI: 10.1371/journal.pone.0249426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Kim JS, Choi GH, Jung Y, Kim KM, Jang SJ, Yu ES, Lee HC. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. J Cancer Res Clin Oncol 2018;144:1487-501. [PMID: 29858683 DOI: 10.1007/s00432-018-2672-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
223 Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep 2017;7:44123. [PMID: 28276530 DOI: 10.1038/srep44123] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
224 Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci. 2020;111:2747-2759. [PMID: 32449239 DOI: 10.1111/cas.14497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
225 Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma 2019;6:31-9. [PMID: 30775342 DOI: 10.2147/JHC.S168953] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 11.5] [Reference Citation Analysis]
226 Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol. 2015;21:10336-10347. [PMID: 26420960 DOI: 10.3748/wjg.v21.i36.10336] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
227 Kudo M. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 2020;9:640-62. [PMID: 33442538 DOI: 10.1159/000511001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 21.0] [Reference Citation Analysis]
228 Panvichian R, Tantiwetrueangdet A, Sornmayura P, Leelaudomlipi S. Missense Mutations in Exons 18-24 of EGFR in Hepatocellular Carcinoma Tissues. Biomed Res Int 2015;2015:171845. [PMID: 26436086 DOI: 10.1155/2015/171845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
229 Liapi E, Geschwind JF. Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma. Liver Cancer. 2012;1:201-215. [PMID: 24159585 DOI: 10.1159/000343835] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
230 Jiang W, Li T, Guo J, Wang J, Jia L, Shi X, Yang T, Jiao R, Wei X, Feng Z, Tang Q, Ji G. Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. Front Oncol 2021;11:546586. [PMID: 33777728 DOI: 10.3389/fonc.2021.546586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Park JO, Ryoo BY, Yen CJ, Kudo M, Yang L, Abada PB, Cheng R, Orlando M, Zhu AX, Okusaka T. Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget. 2016;7:75482-75491. [PMID: 27776351 DOI: 10.18632/oncotarget.12780] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
232 Pfeiffenberger J, Koschny R, Hoffmann K, Mehrabi A, Schmitz A, Radeleff B, Stremmel W, Schemmer P, Ganten TM. Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. Langenbecks Arch Surg. 2013;398:1123-1128. [PMID: 24091908 DOI: 10.1007/s00423-013-1114-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
233 Shrestha R, Bridle KR, Cao L, Crawford DHG, Jayachandran A. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells. Curr Oncol 2021;28:2150-72. [PMID: 34208001 DOI: 10.3390/curroncol28030200] [Reference Citation Analysis]
234 Jiang N, Zhang X, Qin D, Yang J, Wu A, Wang L, Sun Y, Li H, Shen X, Lin J, Kantawong F, Wu J. Identification of Core Genes Related to Progression and Prognosis of Hepatocellular Carcinoma and Small-Molecule Drug Predication. Front Genet 2021;12:608017. [PMID: 33708237 DOI: 10.3389/fgene.2021.608017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Almhanna K, Philip PA. Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco Targets Ther 2009;2:261-7. [PMID: 20616913 DOI: 10.2147/ott.s5548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
236 Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK; Asia-Pacific Hepatocellular Carcinoma Trials Group. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer 2016;16:856. [PMID: 27821083 DOI: 10.1186/s12885-016-2868-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
237 Koga Y, Beppu T, Imai K, Kuramoto K, Miyata T, Kitano Y, Nakagawa S, Okabe H, Okabe K, Yamashita YI, Chikamoto A, Baba H. Complete remission of advanced hepatocellular carcinoma following transient chemoembolization and portal vein ligation. Surg Case Rep 2018;4:102. [PMID: 30159613 DOI: 10.1186/s40792-018-0510-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
238 Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist. 2014;19:394-402. [PMID: 24652387 DOI: 10.1634/theoncologist.2013-0114] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 12.3] [Reference Citation Analysis]
239 Saka H, Kitagawa C, Kogure Y, Takahashi Y, Fujikawa K, Sagawa T, Iwasa S, Takahashi N, Fukao T, Tchinou C, Landers D, Yamada Y. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. Invest New Drugs 2017;35:451-62. [PMID: 28070720 DOI: 10.1007/s10637-016-0416-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
240 Hu H, Duan Z, Long X, Hertzanu Y, Shi H, Liu S, Yang Z. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PLoS One. 2014;9:e96620. [PMID: 24817002 DOI: 10.1371/journal.pone.0096620] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
241 Wang WJ, Wang H, Hua TY, Song W, Zhu J, Wang JJ, Huang YQ, Ding ZL. Establishment of a Prognostic Model Using Immune-Related Genes in Patients With Hepatocellular Carcinoma. Front Genet 2020;11:55. [PMID: 32158466 DOI: 10.3389/fgene.2020.00055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
242 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms] [Cited by in Crossref: 22] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
243 Yang KL, Chi MS, Ko HL, Huang YY, Huang SC, Lin YM, Chi KH. Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. Radiat Oncol 2021;16:18. [PMID: 33472666 DOI: 10.1186/s13014-020-01742-w] [Reference Citation Analysis]
244 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021;27:2434-57. [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, Liu P, Zhu LZ, Xu HF, Yang RJ. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. Biomed Res Int 2021;2021:6670367. [PMID: 34337041 DOI: 10.1155/2021/6670367] [Reference Citation Analysis]
246 Mo HN, Liu P. Targeting MET in cancer therapy. Chronic Dis Transl Med 2017;3:148-53. [PMID: 29063069 DOI: 10.1016/j.cdtm.2017.06.002] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 13.3] [Reference Citation Analysis]
247 Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695-704. [PMID: 21147504 DOI: 10.1016/j.jhep.2010.10.004] [Cited by in Crossref: 124] [Cited by in F6Publishing: 104] [Article Influence: 11.3] [Reference Citation Analysis]
248 Deng L, Sun J, Chen X, Liu L, Wu D. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:316. [PMID: 31319849 DOI: 10.1186/s13046-019-1311-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
249 Memeo R, de Blasi V, Cherkaoui Z, Dehlawi A, De' Angelis N, Piardi T, Sommacale D, Marescaux J, Mutter D, Pessaux P. New Approaches in Locoregional Therapies for Hepatocellular Carcinoma. J Gastrointest Cancer 2016;47:239-46. [PMID: 27270711 DOI: 10.1007/s12029-016-9840-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
250 Shomura M, Kagawa T, Okabe H, Shiraishi K, Hirose S, Arase Y, Tsuruya K, Takahira S, Mine T. Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. BMC Cancer. 2016;16:878. [PMID: 27835949 DOI: 10.1186/s12885-016-2908-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
251 Yang T, Lin C, Zhai J, Shi S, Zhu M, Zhu N, Lu JH, Yang GS, Wu MC. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. J Cancer Res Clin Oncol. 2012;138:1121-1129. [PMID: 22402598 DOI: 10.1007/s00432-012-1188-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
252 Wei T, Zhang LN, Lv Y, Ma XY, Zhi L, Liu C, Ma F, Zhang XF. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 2014;5:10307-10317. [PMID: 25333264 DOI: 10.18632/oncotarget.2537] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
253 Ma KW, Cheung TT. Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration. J Hepatocell Carcinoma. 2016;4:1-9. [PMID: 28097107 DOI: 10.2147/jhc.s96085] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
254 Tsai TH, Chen YJ, Wang LY, Hsieh CH. Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation. Pharmaceutics 2021;13:386. [PMID: 33805831 DOI: 10.3390/pharmaceutics13030386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
255 Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer 2014;3:405-16. [PMID: 26280002 DOI: 10.1159/000343861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
256 Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol. 2014;20:786-794. [PMID: 24574751 DOI: 10.3748/wjg.v20.i3.786] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
257 Güney İB. HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT). J Gastrointest Cancer 2017;48:276-80. [PMID: 28634672 DOI: 10.1007/s12029-017-9973-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
258 Sun X, Niu X, Chen R, He W, Chen D, Kang R, Tang D. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 2016;64:488-500. [PMID: 27015352 DOI: 10.1002/hep.28574] [Cited by in Crossref: 167] [Cited by in F6Publishing: 156] [Article Influence: 33.4] [Reference Citation Analysis]
259 Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013;24:1900-1907. [PMID: 23519998 DOI: 10.1093/annonc/mdt109] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
260 Ahn SY, Lee HS, Kweon YO, Tak WY, Park SY. Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy. Dig Dis Sci. 2013;58:1428-1432. [PMID: 23306847 DOI: 10.1007/s10620-012-2522-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
261 Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22:7645-7659. [PMID: 27678348 DOI: 10.3748/wjg.v22.i34.7645] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 63] [Article Influence: 16.8] [Reference Citation Analysis]
262 Fang S, Qiu J, Wu Z, Bai T, Guo W. Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin. Oncotarget 2017;8:49783-95. [PMID: 28572537 DOI: 10.18632/oncotarget.17939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
263 Bao MH, Wong CC. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells 2021;10:1715. [PMID: 34359884 DOI: 10.3390/cells10071715] [Reference Citation Analysis]
264 Ohya K, Kawaoka T, Namba M, Uchikawa S, Kodama K, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Yamauchi M, Imamura M, Chayama K, Aikata H. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. Sci Rep 2019;9:12101. [PMID: 31431642 DOI: 10.1038/s41598-019-48045-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
265 Yu HC, Lin CS, Tai WT, Liu CY, Shiau CW, Chen KF. Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation. J Biol Chem. 2013;288:18249-18259. [PMID: 23677989 DOI: 10.1074/jbc.m112.446385] [Cited by in Crossref: 65] [Cited by in F6Publishing: 32] [Article Influence: 8.1] [Reference Citation Analysis]
266 He S, Wei H, Ma Y, Zhao J, Xu W, Xiao J. Outcomes of metastatic spinal cord compression secondary to primary hepatocellular carcinoma with multidisciplinary treatments. Oncotarget 2017;8:43439-49. [PMID: 28404935 DOI: 10.18632/oncotarget.15708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
267 Endo M, Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience. Mol Clin Oncol 2016;4:515-22. [PMID: 27073653 DOI: 10.3892/mco.2016.755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
268 Okusaka T, Otsuka T, Ueno H, Mitsunaga S, Sugimoto R, Muro K, Saito I, Tadayasu Y, Inoue K, Loembé AB, Ikeda M. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Sci 2016;107:1791-9. [PMID: 27627050 DOI: 10.1111/cas.13077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
269 Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545-551. [PMID: 27816492 DOI: 10.1016/j.jhep.2016.10.029] [Cited by in Crossref: 296] [Cited by in F6Publishing: 268] [Article Influence: 59.2] [Reference Citation Analysis]
270 Obi S, Sato T, Sato S, Kanda M, Tokudome Y, Kojima Y, Suzuki Y, Hosoda K, Kawai T, Kondo Y, Isomura Y, Ohyama H, Nakagomi K, Ashizawa H, Miura Y, Amano H, Mochizuki H, Omata M. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatol Int. 2019;13:199-204. [PMID: 30671808 DOI: 10.1007/s12072-019-09929-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
271 Imamura A, Taguchi H, Takano H, Funatsu H, Nakamura K, Arimitsu H, Chiba S. Whole-liver transcatheter arterial chemoinfusion and bland embolization with fine-powder cisplatin and trisacryl gelatin microspheres for treating unresectable multiple hepatocellular carcinoma. Jpn J Radiol 2021;39:494-502. [PMID: 33387186 DOI: 10.1007/s11604-020-01078-1] [Reference Citation Analysis]
272 Li J, Shi L, Zhang X, Sun B, Yang Y, Ge N, Liu H, Yang X, Chen L, Qian H. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncotarget. 2016;7:2646-2659. [PMID: 26544731 DOI: 10.18632/oncotarget.6104] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
273 Greten TF, Forner A, Korangy F, N’Kontchou G, Barget N, Ayuso C, Ormandy LA, Manns MP, Beaugrand M, Bruix J. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010;10:209. [PMID: 20478057 DOI: 10.1016/s0168-8278(10)60217-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
274 Hsu CH, Shen YC, Shao YY, Hsu C, Cheng AL. Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. J Hepatocell Carcinoma 2014;1:85-99. [PMID: 27508178 DOI: 10.2147/JHC.S45040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
275 Zhang H, Dong B, Lu JJ, Yao X, Zhang S, Dai B, Shen Y, Zhu Y, Ye D, Huang Y. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer 2009;9:249. [PMID: 19622166 DOI: 10.1186/1471-2407-9-249] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
276 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 7.4] [Reference Citation Analysis]
277 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
278 Gong J, Cho M, Fakih M. Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. J Gastrointest Oncol 2017;8:314-23. [PMID: 28480070 DOI: 10.21037/jgo.2016.09.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
279 Peungjesada S, Chuang HH, Prasad SR, Choi H, Loyer EM, Bronstein Y. Evaluation of cancer treatment in the abdomen: Trends and advances. World J Radiol 2013;5:126-42. [PMID: 23671749 DOI: 10.4329/wjr.v5.i3.126] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
280 Mohamed A, Chenna A, Abdelfatah M, Sanjay J, Mohammad MK, Saber I, Kauh J, Elhammali B, Kaseb A. Microvessel density analysis in patients with viral hepatitis-related hepatocellular carcinoma. J Gastrointest Cancer 2015;46:104-8. [PMID: 25645584 DOI: 10.1007/s12029-015-9684-5] [Reference Citation Analysis]
281 Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology. 2015;61:1591-1602. [PMID: 25529917 DOI: 10.1002/hep.27665] [Cited by in Crossref: 228] [Cited by in F6Publishing: 216] [Article Influence: 38.0] [Reference Citation Analysis]
282 Wee CW, Kim K, Chie EK, Yu SJ, Kim YJ, Yoon JH. Prognostic stratification and nomogram for survival prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis. Br J Radiol 2016;89:20160383. [PMID: 27416997 DOI: 10.1259/bjr.20160383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
283 Zhuang PY, Zhang KW, Wang JD, Zhou XP, Liu YB, Quan ZW, Shen J. Effect of TALEN-mediated IL-6 knockout on cell proliferation, apoptosis, invasion and anti-cancer therapy in hepatocellular carcinoma (HCC-LM3) cells. Oncotarget 2017;8:77915-27. [PMID: 29100435 DOI: 10.18632/oncotarget.20946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
284 Wang L, Ke J, Wang C, Li Y, Wu G, Ding Q, Luo Q, Cai R, Lv P, Song T, Xiong S. Efficacy and Safety of Banxia XieXin Decoction, a Blended Traditional Chinese Medicine, as Monotherapy for Patients With Advanced Hepatocellular Carcinoma. Integr Cancer Ther 2020;19:1534735420942587. [PMID: 32787468 DOI: 10.1177/1534735420942587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
285 Zahavi T, Lanton T, Divon MS, Salmon A, Peretz T, Galun E, Axelrod JH, Sonnenblick A. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. Oncotarget 2016;7:4860-70. [PMID: 26695439 DOI: 10.18632/oncotarget.6638] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
286 Ogasawara S, Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N. Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clin Mol Hepatol. 2020;26:155-162. [PMID: 31937081 DOI: 10.3350/cmh.2019.0021n] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
287 Zhu N, Weng S, Wang J, Chen J, Yu L, Fang X, Yuan Y. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. J Cancer Res Clin Oncol 2019;145:3021-36. [PMID: 31617075 DOI: 10.1007/s00432-019-03044-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
288 Yoon EL, Yeon JE, Ko E, Lee HJ, Je JH, Yoo YJ, Kang SH, Suh SJ, Kim JH, Seo YS. An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma. J Korean Med Sci. 2017;32:212-220. [PMID: 28049231 DOI: 10.3346/jkms.2017.32.2.212] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
289 Nakamura K, Beppu T, Hayashi H, Okabe H, Imai K, Nitta H, Chikamoto A, Ishiko T, Sasaki M, Baba H. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection. Int Surg. 2015;100:908-914. [PMID: 26011214 DOI: 10.9738/intsurg-d-14-00133.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
290 Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011;8:292-301. [PMID: 21386818 DOI: 10.1038/nrclinonc.2011.30] [Cited by in Crossref: 293] [Cited by in F6Publishing: 281] [Article Influence: 29.3] [Reference Citation Analysis]
291 Aishanjiang K, Wei XD, Fu Y, Lin X, Ma Y, Le J, Han Q, Wang X, Kong X, Gu J, Wu H. Circular RNAs and Hepatocellular Carcinoma: New Epigenetic Players With Diagnostic and Prognostic Roles. Front Oncol 2021;11:653717. [PMID: 33959506 DOI: 10.3389/fonc.2021.653717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
292 Connell LC, Harding JJ, Abou-Alfa GK. Advanced Hepatocellular Cancer: the Current State of Future Research. Curr Treat Options Oncol. 2016;17:43. [PMID: 27344158 DOI: 10.1007/s11864-016-0415-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
293 Luo XY, Wu KM, He XX. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res 2021;40:172. [PMID: 34006331 DOI: 10.1186/s13046-021-01968-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
294 Lim C, Compagnon P, Sebagh M, Salloum C, Calderaro J, Luciani A, Pascal G, Laurent A, Levesque E, Maggi U, Feray C, Cherqui D, Castaing D, Azoulay D. Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgery. HPB (Oxford). 2015;17:611-623. [PMID: 25980326 DOI: 10.1111/hpb.12416] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
295 Peveling-Oberhag J, Seiz A, Döring C, Hartmann S, Köberle V, Liese J, Zeuzem S, Hansmann ML, Piiper A. MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule. Transl Oncol 2014;7:672-80. [PMID: 25500075 DOI: 10.1016/j.tranon.2014.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
296 Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, Ward SC, Sun X, Song WM, Koh A, Canasto-Chibuque C. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int. 2016;36:108-118. [PMID: 26058462 DOI: 10.1111/liv.12889] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
297 Wertheim JA, Petrowsky H, Saab S, Kupiec-Weglinski JW, Busuttil RW. Major challenges limiting liver transplantation in the United States. Am J Transplant. 2011;11:1773-1784. [PMID: 21672146 DOI: 10.1111/j.1600-6143.2011.03587.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 90] [Article Influence: 11.0] [Reference Citation Analysis]
298 Oyama K, Koda M, Sugihara T, Kishina M, Miyoshi K, Okamoto T, Hodotsuka M, Fujise Y, Matono T, Tokunaga S, Okamoto K, Hosho K, Okano J, Murawaki Y. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol 2015;3:655-62. [PMID: 26137283 DOI: 10.3892/mco.2015.523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
299 Liu Z, Li X, He X, Xu Y, Wang X. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report. BMC Cancer. 2019;19:1062. [PMID: 31703571 DOI: 10.1186/s12885-019-6287-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
300 Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget. 2017;8:41242-41255. [PMID: 28465485 DOI: 10.18632/oncotarget.17168] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 15.0] [Reference Citation Analysis]
301 Zhang XH, Cao MQ, Li XX, Zhang T. Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World J Hepatol 2020;12:766-74. [PMID: 33200015 DOI: 10.4254/wjh.v12.i10.766] [Reference Citation Analysis]
302 Kong JY, Li SM, Fan HY, Zhang L, Zhao HJ, Li SM. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e11872. [PMID: 30113483 DOI: 10.1097/MD.0000000000011872] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
303 Qiu Z, Shen L, Jiang Y, Qiu J, Xu Z, Shi M, Yu Z, Ma Y, He W, Zheng Y, Li B, Wang G, Yuan Y. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study. Ann Transl Med 2021;9:283. [PMID: 33708910 DOI: 10.21037/atm-20-5360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis. 2013;4:e485. [PMID: 23392173 DOI: 10.1038/cddis.2013.18] [Cited by in Crossref: 120] [Cited by in F6Publishing: 124] [Article Influence: 15.0] [Reference Citation Analysis]
305 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
306 Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M. The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization. Liver Cancer 2017;6:227-35. [PMID: 28626733 DOI: 10.1159/000475777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
307 Dong M, Wang R, Sun P, Zhang D, Zhang Z, Zhang J, Tse G, Zhong L. Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs. Oncol Lett 2021;21:315. [PMID: 33692847 DOI: 10.3892/ol.2021.12576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
308 Li Y, Lu J, Chen Q, Han S, Shao H, Chen P, Jin Q, Yang M, Shangguan F, Fei M, Wang L, Liu Y, Liu N, Lu B. Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling. Arch Toxicol 2019;93:3367-83. [PMID: 31563988 DOI: 10.1007/s00204-019-02579-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
309 Sánchez AIP, Roces LV, García IZ, López EL, Hernandez MAC, Parejo MIB, Peña-Díaz J. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett 2018;15:8863-70. [PMID: 29805623 DOI: 10.3892/ol.2018.8400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
310 Gupta M, Iyer RV. Hepatocellular Carcinoma: Special Issue Highlights. Cancers (Basel) 2020;12:E2026. [PMID: 32722037 DOI: 10.3390/cancers12082026] [Reference Citation Analysis]
311 Rodríguez-Hernández A, Navarro-Villarán E, González R, Pereira S, Soriano-De Castro LB, Sarrias-Giménez A, Barrera-Pulido L, Álamo-Martínez JM, Serrablo-Requejo A, Blanco-Fernández G, Nogales-Muñoz A, Gila-Bohórquez A, Pacheco D, Torres-Nieto MA, Serrano-Díaz-Canedo J, Suárez-Artacho G, Bernal-Bellido C, Marín-Gómez LM, Barcena JA, Gómez-Bravo MA, Padilla CA, Padillo FJ, Muntané J. Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells. Redox Biol 2015;6:174-82. [PMID: 26233703 DOI: 10.1016/j.redox.2015.07.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
312 Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, Bae SH, Choi JY, Yoon SK. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol 2017;9:615-26. [PMID: 28974984 DOI: 10.1177/1758834017728018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
313 Li JQ, Wu X, Gan L, Yang XL, Miao ZH. Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells. Acta Pharmacol Sin 2017;38:1642-54. [PMID: 28713155 DOI: 10.1038/aps.2017.79] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
314 Wang W, Guo Y, Zhong J, Wang Q, Wang X, Wei H, Li J, Xiu P. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Sci Rep 2021;11:2415. [PMID: 33510294 DOI: 10.1038/s41598-021-82058-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
315 Shindoh J, Kaseb A, Vauthey JN. Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer 2013;2:47-54. [PMID: 24159596 DOI: 10.1159/000346222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
316 Kaneko S, Ikeda K, Matsuzaki Y, Furuse J, Minami H, Okayama Y, Sunaya T, Ito Y, Inuyama L, Okita K. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol 2016;51:1011-21. [PMID: 26931117 DOI: 10.1007/s00535-016-1173-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
317 Wörns MA, Galle PR. Sorafenib for the treatment of hepatocellular carcinoma. Hepat Oncol 2014;1:189-204. [PMID: 30190954 DOI: 10.2217/hep.13.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
318 Zhang K, Chen J, Zhou H, Chen Y, Zhi Y, Zhang B, Chen L, Chu X, Wang R, Zhang C. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib. Cell Death Dis 2018;9:312. [PMID: 29472524 DOI: 10.1038/s41419-018-0344-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 16.3] [Reference Citation Analysis]
319 Kiruthiga C, Devi KP, Nabavi SM, Bishayee A. Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E562. [PMID: 32121322 DOI: 10.3390/cancers12030562] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
320 Wu MY, Tang YP, Liu JJ, Liang R, Luo XL. Global transcriptomic study of circRNAs expression profile in sorafenib resistant hepatocellular carcinoma cells. J Cancer 2020;11:2993-3001. [PMID: 32226514 DOI: 10.7150/jca.39854] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
321 Reddy NN, Hung SJ, Swamy MK, Sanjeev A, Rao VS, Rohini R, Raju AK, Bhaskar K, Hu A, Reddy PM. Synthesis and Rational Design of New Appended 1,2,3-Triazole-uracil Ensembles as Promising Anti-Tumor Agents via In Silico VEGFR-2 Transferase Inhibition. Molecules 2021;26:1952. [PMID: 33808444 DOI: 10.3390/molecules26071952] [Reference Citation Analysis]
322 Shek FH, Luo R, Lam BYH, Sung WK, Lam TW, Luk JM, Leung MS, Chan KT, Wang HK, Chan CM, Poon RT, Lee NP. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma. Cell Oncol (Dordr) 2017;40:443-56. [PMID: 28631187 DOI: 10.1007/s13402-017-0332-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
323 Tsuji K, Takemura K, Minami K, Teramoto R, Nakashima K, Yamada S, Doyama H, Oiwake H, Hasatani K. A case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma. Clin J Gastroenterol 2013;6:255-7. [PMID: 23766825 DOI: 10.1007/s12328-013-0381-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
324 Sinn DH, Gwak GY, Cho J, Paik SW, Yoo BC. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. PLoS One. 2014;9:e112184. [PMID: 25372403 DOI: 10.1371/journal.pone.0112184] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
325 Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-233. [PMID: 19167326 DOI: 10.1016/j] [Cited by in F6Publishing: 93] [Reference Citation Analysis]
326 Ye SL, Yang J, Bie P, Zhang S, Chen X, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Lv Z. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. BMC Cancer 2018;18:247. [PMID: 29499662 DOI: 10.1186/s12885-018-4144-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
327 Hosseini S, Chamani J, Sinichi M, Bonakdar AM, Azad Z, Ahangari N, Rahimi HR. The effect of nanomicelle curcumin, sorafenib, and combination of the two on the cyclin D1 gene expression of the hepatocellular carcinoma cell line (HUH7). Iran J Basic Med Sci 2019;22:1198-202. [PMID: 31998463 DOI: 10.22038/ijbms.2019.35808.8530] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
328 Lee DY, Park JW, Kim TH, Lee JH, Kim BH, Woo SM, Kim SS, Lee WJ, Kim DY, Kim CM. Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma. Strahlenther Onkol 2015;191:835-44. [PMID: 26174506 DOI: 10.1007/s00066-015-0873-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
329 Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013;19:6614-6623. [PMID: 24088738 DOI: 10.1158/1078-0432.ccr-13-1442] [Cited by in Crossref: 99] [Cited by in F6Publishing: 49] [Article Influence: 12.4] [Reference Citation Analysis]
330 El Shorbagy S, abuTaleb F, Labib HA, Ebian H, Harb OA, Mohammed MS, Rashied HA, Elbana KA, Haggag R. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination. J Gastrointest Cancer 2021;52:269-79. [PMID: 32212089 DOI: 10.1007/s12029-020-00389-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
331 Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells. PLoS One 2017;12:e0185088. [PMID: 28934275 DOI: 10.1371/journal.pone.0185088] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
332 Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol. 2015;7:1020-1029. [PMID: 26052391 DOI: 10.4254/wjh.v7.i8.1020] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 13.0] [Reference Citation Analysis]
333 Ao L, Song X, Li X, Tong M, Guo Y, Li J, Li H, Cai H, Li M, Guan Q, Yan H, Guo Z. An individualized prognostic signature and multi‑omics distinction for early stage hepatocellular carcinoma patients with surgical resection. Oncotarget 2016;7:24097-110. [PMID: 27006471 DOI: 10.18632/oncotarget.8212] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
334 Wu FH, Shen CH, Luo SC, Hwang JI, Chao WS, Yeh HZ, Jan YG, Yen Y, Cheng SB, Wu CC, Lin YL, P'eng FK. Liver resection for hepatocellular carcinoma in oldest old patients. World J Surg Oncol 2019;17:1. [PMID: 30606220 DOI: 10.1186/s12957-018-1541-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
335 Rovesti G, Orsi G, Kalliopi A, Vivaldi C, Marisi G, Faloppi L, Foschi FG, Silvestris N, Pecora I, Aprile G, Molinaro E, Riggi L, Ulivi P, Canale M, Cucchetti A, Tamburini E, Ercolani G, Fornaro L, Andreone P, Zavattari P, Scartozzi M, Cascinu S, Casadei-Gardini A. Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointest Tumors 2019;6:92-107. [PMID: 31768353 DOI: 10.1159/000502714] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
336 Enomoto H, Nakamura H, Liu W, Nishiguchi S. Hepatoma-Derived Growth Factor: Its Possible Involvement in the Progression of Hepatocellular Carcinoma. Int J Mol Sci 2015;16:14086-97. [PMID: 26101867 DOI: 10.3390/ijms160614086] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
337 Walcott-Sapp S, Naugler S, Lim JY, Wagner J, Orloff SL, Farsad K, Kolbeck KJ, Kaufman J, Maynard E, Enestvedt CK, Mayo SC, Billingsley KG. Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center. J Gastrointest Oncol 2018;9:1074-83. [PMID: 30603126 DOI: 10.21037/jgo.2018.08.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
338 Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist 2010;15:683-94. [PMID: 20547589 DOI: 10.1634/theoncologist.2009-0235] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
339 Terashima T, Yamashita T, Toyama T, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Liver Cancer 2019;8:130-9. [PMID: 31019903 DOI: 10.1159/000489505] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
340 Xu G, Jin B, Xian X, Yang H, Zhao H, Du S, Makuuchi M, Pawlik TM, Mao Y. Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer 2021;10:137-50. [PMID: 33977090 DOI: 10.1159/000513412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
341 Lee DW, Lee KH, Kim HJ, Kim TY, Kim JS, Han SW, Oh DY, Kim JH, Im SA, Kim TY. A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. BMC Cancer 2018;18:252. [PMID: 29506478 DOI: 10.1186/s12885-018-4039-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
342 Ogasawara S, Chiba T, Ooka Y, Suzuki E, Inoue M, Wakamatsu T, Tawada A, Yokosuka O. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0161303. [PMID: 27537374 DOI: 10.1371/journal.pone.0161303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
343 Liang Y, Chen J, Yu Q, Ji T, Zhang B, Xu J, Dai Y, Xie Y, Lin H, Liang X. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. Cancer Med. 2017;6:2787-2795. [PMID: 29030911 DOI: 10.1002/cam4.1228] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
344 Mei J, Tang YH, Wei W, Shi M, Zheng L, Li SH, Guo RP. Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. Front Oncol 2021;11:618206. [PMID: 33718175 DOI: 10.3389/fonc.2021.618206] [Reference Citation Analysis]
345 Xu J, Zheng L, Chen J, Sun Y, Lin H, Jin RA, Tang M, Liang X, Cai X. Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death Dis 2017;8:e3095. [PMID: 29022906 DOI: 10.1038/cddis.2017.411] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
346 Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kasuya K, Sano T, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. Liver Cancer 2020;9:275-92. [PMID: 32647631 DOI: 10.1159/000505190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
347 Rani B, Cao Y, Malfettone A, Tomuleasa C, Fabregat I, Giannelli G. Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2014;20:4128-4140. [PMID: 24764651 DOI: 10.3748/wjg.v20.i15.4128] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
348 Zhu Q, Ren H, Li X, Qian B, Fan S, Hu F, Xu L, Zhai B. Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma. Aging (Albany NY) 2020;12:22975-3003. [PMID: 33203790 DOI: 10.18632/aging.104028] [Reference Citation Analysis]
349 Ding W, Tan Y, Qian Y, Xue W, Wang Y, Jiang P, Xu X. First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials. PLoS One 2020;15:e0229492. [PMID: 32134981 DOI: 10.1371/journal.pone.0229492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 81] [Article Influence: 21.6] [Reference Citation Analysis]
351 Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore). 2015;94:e688. [PMID: 25860213 DOI: 10.1097/md.0000000000000688] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
352 Bruera G, Cannita K, Giordano AV, Manetta R, Vicentini R, Carducci S, Saltarelli P, Iapadre N, Coletti G, Ficorella C. Multidisciplinary management of hepatocellular carcinoma in clinical practice. Biomed Res Int. 2014;2014:806391. [PMID: 24900987 DOI: 10.1155/2014/806391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
353 Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang X, Wang Z, Yang Y, Chen C, Wang Z. The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells. Oncotarget. 2015;6:7000-7010. [PMID: 25760076 DOI: 10.18632/oncotarget.3193] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
354 Jiang JM, Ohri N, Tang J, Moadel R, Cynamon J, Kaubisch A, Kinkhabwala M, Garg MK, Guha C, Kabarriti R. Centers with more therapeutic modalities are associated with improved outcomes for patients with hepatocellular carcinoma. J Gastrointest Oncol 2019;10:546-53. [PMID: 31183206 DOI: 10.21037/jgo.2019.01.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
355 Shinoda M, Kishida N, Itano O, Ei S, Ueno A, Kitago M, Abe Y, Hibi T, Yagi H, Masugi Y. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature. World J Surg Oncol. 2015;13:144. [PMID: 25889667 DOI: 10.1186/s12957-015-0559-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
356 Lee EW, Alanis L, Cho SK, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol. 2016;17:472-488. [PMID: 27390539 DOI: 10.3348/kjr.2016.17.4.472] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
357 Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers (Basel). 2019;11. [PMID: 31216701 DOI: 10.3390/cancers11060841] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
358 Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 2013;43:147-154. [PMID: 23145926 DOI: 10.1111/j.1872-034x.2012.01113] [Reference Citation Analysis]
359 Chung YG, Tak E, Hwang S, Lee JY, Kim JY, Kim YY, Song GW, Lee KJ, Kim N. Synergistic effect of metformin on sorafenib in in vitro study using hepatocellular carcinoma cell lines. Ann Hepatobiliary Pancreat Surg 2018;22:179-84. [PMID: 30215039 DOI: 10.14701/ahbps.2018.22.3.179] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
360 Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon 2012;12:e7635. [PMID: 23233865 DOI: 10.5812/hepatmon.7635] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
361 Yen CJ, Kim TY, Feng YH, Chao Y, Lin DY, Ryoo BY, Huang DC, Schnell D, Hocke J, Loembé AB, Cheng AL. A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2018;7:165-78. [PMID: 29888206 DOI: 10.1159/000486460] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
362 Mancuso A, Perricone G. Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol 2014;2:176-81. [PMID: 26357625 DOI: 10.14218/JCTH.2014.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
363 He M, Hou J, Wang L, Zheng M, Fang T, Wang X, Xia J. Actinidia chinensis Planch root extract inhibits cholesterol metabolism in hepatocellular carcinoma through upregulation of PCSK9. Oncotarget 2017;8:42136-48. [PMID: 28178673 DOI: 10.18632/oncotarget.15010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
364 Tang S, Tan G, Jiang X, Han P, Zhai B, Dong X, Qiao H, Jiang H, Sun X. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. Oncotarget 2016;7:73257-69. [PMID: 27689326 DOI: 10.18632/oncotarget.12304] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 14.3] [Reference Citation Analysis]
365 Kim N, You MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. Jpn J Radiol 2019;37:781-92. [PMID: 31522384 DOI: 10.1007/s11604-019-00868-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
366 Yu L, Wang Z, Mo Z, Zou B, Yang Y, Sun R, Ma W, Yu M, Zhang S, Yu Z. Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy. Acta Pharm Sin B 2021;11:2004-15. [PMID: 34386334 DOI: 10.1016/j.apsb.2021.02.001] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
367 Woller N, Engelskircher SA, Wirth T, Wedemeyer H. Prospects and Challenges for T Cell-Based Therapies of HCC. Cells 2021;10:1651. [PMID: 34209393 DOI: 10.3390/cells10071651] [Reference Citation Analysis]
368 Hosseinzadeh F, Verdi J, Ai J, Hajighasemlou S, Seyhoun I, Parvizpour F, Hosseinzadeh F, Iranikhah A, Shirian S. Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review. Cancer Cell Int 2018;18:133. [PMID: 30214375 DOI: 10.1186/s12935-018-0624-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
369 Mee CJ, Farquhar MJ, Harris HJ, Hu K, Ramma W, Ahmed A, Maurel P, Bicknell R, Balfe P, McKeating JA. Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology. 2010;138:1134-1142. [PMID: 19944696 DOI: 10.1053/j.gastro.2009.11.047] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
370 Wong P, Houghton P, Kirsch DG, Finkelstein SE, Monjazeb AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B, Teicher BA, Coleman CN, Machtay M, Curran WJ, Wang D. Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst 2014;106:dju329. [PMID: 25326640 DOI: 10.1093/jnci/dju329] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
371 Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011;117:5094-5102. [PMID: 21538343 DOI: 10.1002/cncr.26165] [Cited by in Crossref: 139] [Cited by in F6Publishing: 128] [Article Influence: 13.9] [Reference Citation Analysis]
372 Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, Park SY, Yang JM. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50:445-454. [PMID: 25027973 DOI: 10.1007/s00535-014-0978-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 9.0] [Reference Citation Analysis]
373 Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, Zhong JH. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget 2017;8:33911-21. [PMID: 28430610 DOI: 10.18632/oncotarget.15411] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
374 Kitajima T, Hatano E, Mitsunori Y, Taura K, Fujimoto Y, Mizumoto M, Okajima H, Kaido T, Minamiguchi S, Uemoto S. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. Clin J Gastroenterol. 2015;8:300-305. [PMID: 26249525 DOI: 10.1007/s12328-015-0594-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
375 Lee YS, Kim BH, Kim BC, Shin A, Kim JS, Hong SH, Hwang JA, Lee JA, Nam S, Lee SH, Bhak J, Park JW. SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma. Oncotarget 2015;6:16449-60. [PMID: 25965825 DOI: 10.18632/oncotarget.3758] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
376 Zhang L, Gong F, Zhang F, Ma J, Zhang P, Shen J. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro. Int J Nanomedicine. 2013;8:1517-1524. [PMID: 23620667 DOI: 10.2147/ijn.s43263] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
377 Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH. National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer. 2016;5:97-106. [PMID: 27386428 DOI: 10.1159/000367759] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
378 Gupta N, Verma RK, Prinja S, Dhiman RK. Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India. J Clin Exp Hepatol 2019;9:468-75. [PMID: 31516263 DOI: 10.1016/j.jceh.2018.10.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
379 Wu B, Jiang Y, Zhu F, Sun D, Huang H. Demethylation effects of elemene on the GSTP1 gene in HCC cell line QGY7703. Oncol Lett 2016;11:2545-51. [PMID: 27073515 DOI: 10.3892/ol.2016.4243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
380 Abou-Alfa GK, Yen CJ, Hsu CH, O'Donoghue J, Beylergil V, Ruan S, Pandit-Taskar N, Gansukh B, Lyashchenko SK, Ma J, Wan P, Shao YY, Lin ZZ, Frenette C, O'Neil B, Schwartz L, Smith-Jones PM, Ohtomo T, Tanaka T, Morikawa H, Maki Y, Ohishi N, Chen YC, Agajanov T, Boisserie F, Di Laurenzio L, Lee R, Larson SM, Cheng AL, Carrasquilo JA. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemother Pharmacol 2017;79:421-9. [PMID: 28120036 DOI: 10.1007/s00280-017-3241-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
381 Zhang ZM, Guo JX, Zhang ZC, Jiang N, Zhang ZY, Pan LJ. Therapeutic options for intermediate-advanced hepatocellular carcinoma. World J Gastroenterol 2011;17:1685-9. [PMID: 21483627 DOI: 10.3748/wjg.v17.i13.1685] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
382 Conroy G, Salleron J, Belle A, Bensenane M, Nani A, Ayav A, Peiffert D, Lopez A, Baumann C, Barraud H, Bronowicki JP. The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib. Oncotarget 2017;8:95853-64. [PMID: 29221172 DOI: 10.18632/oncotarget.21401] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
383 Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Tajima K, Matsuzaki T, Hashimoto S, Ooba K, Kugiyama Y, Yatsuhashi H, Motoyoshi Y, Shigeno M, Kinoshita N, Nakao K. Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. Cancers (Basel). 2019;11:1769. [PMID: 31717674 DOI: 10.3390/cancers11111769] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
384 Huang CC, Hwang JM, Tsai JH, Chen JH, Lin H, Lin GJ, Yang HL, Liu JY, Yang CY, Ye JC. Aqueous Ocimum gratissimum extract induces cell apoptosis in human hepatocellular carcinoma cells. Int J Med Sci 2020;17:338-46. [PMID: 32132869 DOI: 10.7150/ijms.39436] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
385 Zhang H, Li XX, Yang Y, Zhang Y, Wang HY, Zheng XFS. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. Hepatology 2018;67:2271-86. [PMID: 29220539 DOI: 10.1002/hep.29715] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
386 Wang P, Jiang Z, Liu X, Yu K, Wang C, Li H, Zhong L. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma. Cancer Med 2020;9:6972-83. [PMID: 32779397 DOI: 10.1002/cam4.3331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
387 Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One. 2015;10:e0124434. [PMID: 25923439 DOI: 10.1371/journal.pone.0124434] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
388 Bort A, Sánchez BG, Mateos-Gómez PA, Vara-Ciruelos D, Rodríguez-Henche N, Díaz-Laviada I. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib. Mol Oncol 2019;13:1311-31. [PMID: 30959553 DOI: 10.1002/1878-0261.12488] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
389 Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014;68:609-17. [PMID: 24283303 DOI: 10.1111/ijcp.12352] [Cited by in Crossref: 154] [Cited by in F6Publishing: 137] [Article Influence: 19.3] [Reference Citation Analysis]
390 Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology 2013;57:1068-77. [PMID: 23112096 DOI: 10.1002/hep.26120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
391 Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas) 2019;55:E526. [PMID: 31450841 DOI: 10.3390/medicina55090526] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 15.0] [Reference Citation Analysis]
392 Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681-8. [PMID: 23463401 DOI: 10.1007/s00535-013-0770-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
393 Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013;8:e63864. [PMID: 23737955 DOI: 10.1371/journal.pone.0063864] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 9.8] [Reference Citation Analysis]
394 Blumer T, Fofana I, Matter MS, Wang X, Montazeri H, Calabrese D, Coto-Llerena M, Boldanova T, Nuciforo S, Kancherla V, Tornillo L, Piscuoglio S, Wieland S, Terracciano LM, Ng CKY, Heim MH. Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors. Hepatol Commun 2019;3:971-86. [PMID: 31334445 DOI: 10.1002/hep4.1365] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
395 Lee DW, Jang MJ, Lee KH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kim TY, Han SW, Oh DY, Im SA, Kim TY. TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. Br J Cancer 2016;115:1201-5. [PMID: 27736843 DOI: 10.1038/bjc.2016.322] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
396 Sprinzl MF, Kirstein MM, Koch S, Seib ML, Weinmann-Menke J, Lang H, Düber C, Toenges G, Zöller D, Marquardt JU, Wörns MA, Galle PR, Vogel A, Pinter M, Weinmann A. Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. Liver Cancer 2019;8:387-402. [PMID: 31768347 DOI: 10.1159/000492628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
397 Chow AK, Yau SW, Ng L. Novel molecular targets in hepatocellular carcinoma. World J Clin Oncol 2020;11:589-605. [PMID: 32879846 DOI: 10.5306/wjco.v11.i8.589] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
398 Kneuertz PJ, Cosgrove DP, Cameron AM, Kamel IR, Geschwind JF, Herman JM, Pawlik TM. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg 2012;16:874-81. [PMID: 21975686 DOI: 10.1007/s11605-011-1710-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
399 Li L, Kan X, Zhao Y, Liang B, Ye T, Yang L, Zheng C. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma. Int J Med Sci 2021;18:2276-84. [PMID: 33967603 DOI: 10.7150/ijms.55510] [Reference Citation Analysis]
400 Sharma H. Role of external beam radiation therapy in management of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S122-S125. [PMID: 25755603 DOI: 10.1016/j.jceh.2014.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
401 He W, Zheng Y, Zou R, Shen J, Yang J, Qiu J, Tao Q, Liu W, Yang Z, Zhang Y, Li B, Yuan Y. Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study. Cancer Commun (Lond) 2018;38:26. [PMID: 29784036 DOI: 10.1186/s40880-018-0296-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
402 Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med 2010;2:163-73. [PMID: 24367214 DOI: 10.2147/HMER.S7132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
403 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol. 2013;5:302-310. [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
404 Xia S, Pan Y, Liang Y, Xu J, Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine 2020;51:102610. [PMID: 31918403 DOI: 10.1016/j.ebiom.2019.102610] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
405 Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 2015;21:12003-12021. [PMID: 26576088 DOI: 10.3748/wjg.v21.i42.12003] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
406 Cidon EU. Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol 2017;9:797-807. [PMID: 28706578 DOI: 10.4254/wjh.v9.i18.797] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
407 Katayama K, Imai T, Abe Y, Nawa T, Maeda N, Nakanishi K, Wada H, Fukui K, Ito Y, Yokota I, Ohkawa K. Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis. J Clin Med Res 2018;10:765-71. [PMID: 30214648 DOI: 10.14740/jocmr3559w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
408 Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, Park SC, Kim YH. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci. 2013;28:213-219. [PMID: 23400333 DOI: 10.3346/jkms.2013.28.2.213] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
409 Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013;119:1042-1049. [PMID: 23132335 DOI: 10.1002/cncr.27859] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
410 Peng H, Xue R, Ju Z, Qiu J, Wang J, Yan W, Gan X, Tian Y, Shen H, Wang X, Wang X, Ni X, Yu Y, Lu L. Cancer-associated fibroblasts enhance the chemoresistance of CD73+ hepatocellular carcinoma cancer cells via HGF-Met-ERK1/2 pathway. Ann Transl Med 2020;8:856. [PMID: 32793700 DOI: 10.21037/atm-20-1038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
411 Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373. [PMID: 24488546 DOI: 10.1007/s11912-013-0373-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
412 Augello G, Puleio R, Emma MR, Cusimano A, Loria GR, McCubrey JA, Montalto G, Cervello M. A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. Cell Cycle. 2016;15:573-583. [PMID: 26794644 DOI: 10.1080/15384101.2016.1138183] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
413 Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody. Br J Pharmacol 2013;168:658-72. [PMID: 22978563 DOI: 10.1111/j.1476-5381.2012.02212.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
414 Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 2013;43:147-154. [PMID: 23145926 DOI: 10.1111/j.1872-034x.2012.01113.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 75] [Article Influence: 12.6] [Reference Citation Analysis]
415 Wei J, Ye L, Song L, Tang H, Zhang T, Fu B, Zhang Y, Yang Q, Yang Y, Yi S. TSC1/2 mutations-a unique type of mutation suitable for liver transplantation of Hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1074-85. [PMID: 34295558 DOI: 10.21037/jgo-20-378] [Reference Citation Analysis]
416 Menon S, Shin S, Dy G. Advances in Cancer Immunotherapy in Solid Tumors. Cancers (Basel) 2016;8:E106. [PMID: 27886124 DOI: 10.3390/cancers8120106] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 17.6] [Reference Citation Analysis]
417 Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, Kim SH, Lee BS, Kim AN, Chae HB, Kim HS, Lee TH, Kang YW, Lee JD, Lee HY. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. BMC Cancer 2015;15:236. [PMID: 25885683 DOI: 10.1186/s12885-015-1273-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
418 Wei JC, Meng FD, Qu K, Wang ZX, Wu QF, Zhang LQ, Pang Q, Liu C. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1. Acta Pharmacol Sin 2015;36:241-51. [PMID: 25557114 DOI: 10.1038/aps.2014.122] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
419 Brandi G, Venturi M, De Lorenzo S, Garuti F, Frega G, Palloni A, Garajovà I, Abbati F, Saccoccio G, Golfieri R, Pantaleo MA, Barbera MA. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases. Cancer Commun (Lond) 2018;38:41. [PMID: 29941039 DOI: 10.1186/s40880-018-0312-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
420 Repana D, Ross P. Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases 2015;3:294-305. [PMID: 28943626 DOI: 10.3390/diseases3040294] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
421 Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 2015;10:e0118658. [PMID: 25830231 DOI: 10.1371/journal.pone.0118658] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
422 Matsuda Y, Fukumoto M. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 2011;44:183-9. [PMID: 22179180 DOI: 10.1007/s00795-011-0558-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
423 Freise C, Ruehl M, Erben U, Neumann U, Seehofer D, Kim KY, Trowitzsch-Kienast W, Stroh T, Zeitz M, Somasundaram R. A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines. BMC Complement Altern Med. 2011;11:39. [PMID: 21569410 DOI: 10.1186/1472-6882-11-39] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
424 Takeyama H, Beppu T, Higashi T, Kaida T, Arima K, Taki K, Imai K, Nitta H, Hayashi H, Nakagawa S, Okabe H, Hashimoto D, Chikamoto A, Ishiko T, Tanaka M, Sasaki Y, Baba H. Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma. Surg Today 2018;48:431-8. [PMID: 29110089 DOI: 10.1007/s00595-017-1603-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
425 Yacoub JH, Mauro D, Moon A, He AR, Bashir MR, Hsu CC, Fishbein TM, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. Abdom Radiol (NY) 2021;46:3540-8. [PMID: 33864107 DOI: 10.1007/s00261-021-03074-z] [Reference Citation Analysis]
426 Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer 2014;3:119-24. [PMID: 24945002 DOI: 10.1159/000343867] [Cited by in Crossref: 39] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
427 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93. [PMID: 33290597 DOI: 10.1002/cac2.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
428 Sun W, Cabrera R. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies. J Gastrointest Cancer 2018;49:107-15. [PMID: 29453759 DOI: 10.1007/s12029-018-0065-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
429 Hsieh CH, Chen YJ, Tsai TH, Wang LY, Tai HC, Huang HL, Huang YC. Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters. Sci Rep 2020;10:9575. [PMID: 32533042 DOI: 10.1038/s41598-020-66583-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
430 Kollmann D, Selzner N, Selzner M. Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg. 2017;402:863-871. [PMID: 28755240 DOI: 10.1007/s00423-017-1609-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
431 De Lorenzo S, Tovoli F, Barbera MA, Garuti F, Palloni A, Frega G, Garajovà I, Rizzo A, Trevisani F, Brandi G. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. Sci Rep 2018;8:9997. [PMID: 29968763 DOI: 10.1038/s41598-018-28337-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
432 Taketomi A. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma. Int J Clin Oncol. 2016;21:213-218. [PMID: 26899258 DOI: 10.1007/s10147-016-0966-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
433 Kamimura K, Shinagawa-Kobayashi Y, Goto R, Ogawa K, Yokoo T, Sakamaki A, Abe S, Kamimura H, Suda T, Baba H, Tanaka T, Nozawa Y, Koyama N, Takamura M, Kawai H, Yamagiwa S, Aoyagi Y, Terai S. Effective prevention of sorafenib-induced hand-foot syndrome by dried-bonito broth. Cancer Manag Res 2018;10:805-13. [PMID: 29713197 DOI: 10.2147/CMAR.S159370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
434 Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol. 2018;7:17. [PMID: 30087805 DOI: 10.1186/s40164-018-0109-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 14.7] [Reference Citation Analysis]
435 Cho E, Ryu EJ, Jiang F, Jeon UB, Cho M, Kim CH, Kim M, Kim ND, Hwang TH. Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus. Drug Des Devel Ther 2018;12:2467-74. [PMID: 30122903 DOI: 10.2147/DDDT.S171269] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
436 Zheng JF, Lu J, Wang XZ, Guo WH, Zhang JX. Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy. Med Sci Monit 2015;21:1781-91. [PMID: 26092946 DOI: 10.12659/MSM.894669] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
437 Chen BB, Hsu CY, Yu CW, Liang PC, Hsu C, Hsu CH, Cheng AL, Shih TT. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. Eur Radiol 2017;27:3069-79. [PMID: 27957638 DOI: 10.1007/s00330-016-4670-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
438 Liu Y, Chen L, Yuan H, Guo S, Wu G. LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells. Onco Targets Ther 2020;13:1145-57. [PMID: 32103983 DOI: 10.2147/OTT.S229957] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 8.0] [Reference Citation Analysis]
439 Yu SJ, Kim YJ. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol. 2015;7:1553-1561. [PMID: 26085914 DOI: 10.4254/wjh.v7.i11.1553] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
440 Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28. [PMID: 20059340 DOI: 10.1146/annurev.med.080608.100623] [Cited by in Crossref: 160] [Cited by in F6Publishing: 145] [Article Influence: 14.5] [Reference Citation Analysis]
441 Peng SY, Wang XA, Huang CY, Li JT, Hong DF, Wang YF, Xu B. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol 2018;24:4527-35. [PMID: 30386102 DOI: 10.3748/wjg.v24.i40.4527] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
442 Ji XQ, Ruan XJ, Chen H, Chen G, Li SY, Yu B. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Med Sci Monit. 2011;17:RA169-RA176. [PMID: 21804474 DOI: 10.12659/msm.881892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
443 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 120] [Article Influence: 4.3] [Reference Citation Analysis]
444 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7:738-752. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738].] [Reference Citation Analysis]
445 Kosaka Y, Kimura T, Kawaoka T, Ogawa Y, Amioka K, Naruto K, Yoshikawa Y, Kikukawa C, Suehiro Y, Yamaoka K, Ando Y, Uchikawa S, Morio K, Nakahara T, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chosa K, Awai K, Nagata Y, Chayama K, Aikata H. Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. Liver Cancer 2021;10:151-60. [PMID: 33977091 DOI: 10.1159/000513706] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
446 Cheon J, Chon HJ, Bang Y, Park NH, Shin JW, Kim KM, Lee HC, Lee J, Yoo C, Ryoo BY. Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. Liver Cancer 2020;9:613-24. [PMID: 33083284 DOI: 10.1159/000508901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
447 Zhang YF, Wei W, Wang JH, Xu L, Jian PE, Xiao CZ, Zhong XP, Shi M, Guo RP. Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Onco Targets Ther 2016;9:4239-46. [PMID: 27471398 DOI: 10.2147/OTT.S106659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
448 Raoul JL, Adhoute X, Penaranda G, Perrier H, Castellani P, Oules V, Bourlière M. Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. Liver Cancer 2019;8:457-67. [PMID: 31799203 DOI: 10.1159/000497161] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
449 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol. 2019;25:3704-3721. [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 29] [Article Influence: 37.0] [Reference Citation Analysis]
450 Shiozawa K, Watanabe M, Kikuchi Y, Kudo T, Maruyama K, Sumino Y. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study. World J Gastroenterol. 2012;18:5753-5758. [PMID: 23155317 DOI: 10.3748/wjg.v18.i40.5753] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
451 Shao W, Zhang F, Cong N, Li J, Song J. Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma. Oncol Lett 2014;8:2263-6. [PMID: 25289106 DOI: 10.3892/ol.2014.2512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
452 Raoul JL, Adhoute X, Gilabert M, Edeline J. How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World J Hepatol. 2016;8:1541-1546. [PMID: 28050234 DOI: 10.4254/wjh.v8.i35.1541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
453 Hung HC, Lee JC, Wang YC, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1607. [PMID: 33807219 DOI: 10.3390/cancers13071607] [Reference Citation Analysis]
454 Azizi AA, Hadjinicolaou AV, Goncalves C, Duckworth A, Basu B. Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma. Front Oncol 2020;10:570958. [PMID: 33102226 DOI: 10.3389/fonc.2020.570958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
455 Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020;69:1492-501. [PMID: 31801872 DOI: 10.1136/gutjnl-2019-318934] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 31.0] [Reference Citation Analysis]
456 El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. Oncologist 2019;24:747-e218. [PMID: 30598500 DOI: 10.1634/theoncologist.2018-0838] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
457 Zou Y, Ruan S, Jin L, Chen Z, Han H, Zhang Y, Jian Z, Lin Y, Shi N, Jin H. CDK1, CCNB1, and CCNB2 are Prognostic Biomarkers and Correlated with Immune Infiltration in Hepatocellular Carcinoma. Med Sci Monit 2020;26:e925289. [PMID: 32863381 DOI: 10.12659/MSM.925289] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
458 Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Dig Dis Sci. 2019;64:1016-1029. [PMID: 30887150 DOI: 10.1007/s10620-019-05582-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
459 Fung AS, Tam VC, Meyers DE, Sim HW, Knox JJ, Zaborska V, Davies J, Ko YJ, Batuyong E, Samawi H, Cheung WY, Lee-Ying R. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab. Cancer Med 2020;9:4640-7. [PMID: 32378799 DOI: 10.1002/cam4.3116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
460 Xia Y, Zhang J, Ni X. Diagnosis, treatment and prognosis of hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus. Oncol Lett 2020;20:101. [PMID: 32831920 DOI: 10.3892/ol.2020.11962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
461 Sakai K, Takeda H, Nishijima N, Orito E, Joko K, Uchida Y, Izumi N, Nishio K, Osaki Y. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. Oncotarget 2015;6:21636-44. [PMID: 26046304 DOI: 10.18632/oncotarget.4270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
462 Une N, Takano-Kasuya M, Kitamura N, Ohta M, Inose T, Kato C, Nishimura R, Tada H, Miyagi S, Ishida T, Unno M, Kamei T, Gonda K. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Med Oncol 2021;38:60. [PMID: 33881631 DOI: 10.1007/s12032-021-01503-z] [Reference Citation Analysis]
463 Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci 2018;5:181006. [PMID: 30662724 DOI: 10.1098/rsos.181006] [Cited by in Crossref: 124] [Cited by in F6Publishing: 121] [Article Influence: 41.3] [Reference Citation Analysis]
464 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
465 Imedio ER, Beveridge RD, Urtasun JA, Campos GB, Estellés DL, Esparcia MF, Daroqui JC, Huerta ÁS, Ortiz AG, Salcedo JM. Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience. Med Oncol 2014;31:948. [PMID: 24740650 DOI: 10.1007/s12032-014-0948-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
466 Yang B, Wang C, Xie H, Wang Y, Huang J, Rong Y, Zhang H, Kong H, Yang Y, Lu Y. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis 2019;10:784. [PMID: 31611551 DOI: 10.1038/s41419-019-2023-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
467 Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27:3027-3035. [PMID: 19470923 DOI: 10.1200/jco.2008.20.9908] [Cited by in Crossref: 353] [Cited by in F6Publishing: 171] [Article Influence: 29.4] [Reference Citation Analysis]
468 Liang RB, Zhao Y, He MK, Wen DS, Bu XY, Huang YX, Lai ZC, Xu YJ, Kan A, Wei W, Zhang YJ, Chen MS, Guo RP, Li QJ, Shi M. Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. Front Oncol 2021;11:619461. [PMID: 34055599 DOI: 10.3389/fonc.2021.619461] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
469 Saber S, Mahmoud A, Helal N, El-Ahwany E, Abdelghany R. Liver Protective Effects of Renin-Angiotensin System Inhibition Have No Survival Benefits in Hepatocellular Carcinoma Induced By Repetitive Administration of Diethylnitrosamine in Mice. Open Access Maced J Med Sci. 2018;6:955-960. [PMID: 29983784 DOI: 10.3889/oamjms.2018.167] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
470 Lee S, Kim BK, Kim SU, Park Y, Chang S, Park JY, Kim do Y, Ahn SH, Chon CY, Han KH. Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS One. 2013;8:e77240. [PMID: 24155932 DOI: 10.1371/journal.pone.0077240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
471 El Othmany R, Zahir H, Ellouali M, Latrache H. Current Understanding on Adhesion and Biofilm Development in Actinobacteria. Int J Microbiol 2021;2021:6637438. [PMID: 34122552 DOI: 10.1155/2021/6637438] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms20061358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 29.5] [Reference Citation Analysis]
473 Keating GM. Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol. 2017;12:243-253. [PMID: 28299600 DOI: 10.1007/s11523-017-0484-7] [Cited by in Crossref: 95] [Cited by in F6Publishing: 85] [Article Influence: 23.8] [Reference Citation Analysis]
474 Ma D, Wang J, Liu L, Chen M, Wang Z. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study. BMC Cancer 2020;20:936. [PMID: 32993568 DOI: 10.1186/s12885-020-07447-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
475 Moriguchi M, Umemura A, Itoh Y. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. Clin J Gastroenterol 2016;9:184-90. [PMID: 27401471 DOI: 10.1007/s12328-016-0670-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
476 Personeni N, Pressiani T, Santoro A, Rimassa L. Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212533. [PMID: 30002715 DOI: 10.7573/dic.212533] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
477 Vescovo T, Pagni B, Piacentini M, Fimia GM, Antonioli M. Regulation of Autophagy in Cells Infected With Oncogenic Human Viruses and Its Impact on Cancer Development. Front Cell Dev Biol 2020;8:47. [PMID: 32181249 DOI: 10.3389/fcell.2020.00047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
478 Cucchetti A, Piscaglia F, Pinna AD, Djulbegovic B, Mazzotti F, Bolondi L. Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. Liver Cancer. 2017;6:337-348. [PMID: 29234637 DOI: 10.1159/000481314] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
479 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
480 Chen ZH, Zhang XP, Cai XR, Xie SD, Liu MM, Lin JX, Ma XK, Chen J, Lin Q, Dong M, Wu XY, Wen JY, Xu RH. The Predictive Value of Albumin-to-Alkaline Phosphatase Ratio for Overall Survival of Hepatocellular Carcinoma Patients Treated with Trans-Catheter Arterial Chemoembolization Therapy. J Cancer 2018;9:3467-78. [PMID: 30310503 DOI: 10.7150/jca.26120] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
481 Chiang CL, Chan SK, Lee SF, Wong IO, Choi HC. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma. JAMA Netw Open 2021;4:e2033761. [PMID: 33464318 DOI: 10.1001/jamanetworkopen.2020.33761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
482 Zhang Q, Chen H, Li Q, Zang Y, Chen X, Zou W, Wang L, Shen ZY. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Invest New Drugs 2011;29:1360-9. [PMID: 21809025 DOI: 10.1007/s10637-011-9726-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
483 Yang Y, Qin SK, Wu Q, Wang ZS, Zheng RS, Tong XH, Liu H, Tao L, He XD. Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition. Oncol Rep 2014;31:540-50. [PMID: 24317203 DOI: 10.3892/or.2013.2894] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
484 Moser M, Radu IP, Dufour JF. Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib. JGH Open 2021;5:864-70. [PMID: 34386593 DOI: 10.1002/jgh3.12533] [Reference Citation Analysis]
485 Merle P, Camus P, Abergel A, Pageaux GP, Masliah C, Bronowicki JP, Zarski JP, Pelletier G, Bouattour M, Farloux L, Dorval E, Verset G, Si-Ahmed SN, Doffoel M, Couzigou P, Taieb J, Vasseur B, Attali P. Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. ESMO Open 2017;2:e000238. [PMID: 29104762 DOI: 10.1136/esmoopen-2017-000238] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
486 Quagliariello V, Masarone M, Armenia E, Giudice A, Barbarisi M, Caraglia M, Barbarisi A, Persico M. Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells. Oncol Rep 2019;41:1476-86. [PMID: 30569138 DOI: 10.3892/or.2018.6932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
487 Tsuchiya K, Kurosaki M, Sakamoto A, Marusawa H, Kojima Y, Hasebe C, Arai H, Joko K, Kondo M, Tsuji K, Sohda T, Kimura H, Ogawa C, Uchida Y, Wada S, Kobashi H, Furuta K, Shigeno M, Kusakabe A, Akahane T, Narita R, Yoshida H, Mitsuda A, Ide Y, Matsushita T, Izumi N, On Behalf Of Japanese Red Cross Liver Study Group. The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers (Basel) 2021;13:2608. [PMID: 34073396 DOI: 10.3390/cancers13112608] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
488 Shek D, Read SA, Nagrial A, Carlino MS, Gao B, George J, Ahlenstiel G. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. Oncologist 2021;26:e1216-25. [PMID: 33818870 DOI: 10.1002/onco.13776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
489 Burak KW, Sherman M. Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol. 2015;29:178-184. [PMID: 25965437 DOI: 10.1155/2015/824263] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
490 Xie H, Yu H, Tian S, Yang X, Wang X, Yang Z, Wang H, Guo Z. What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis. Oncotarget 2017;8:100508-23. [PMID: 29245997 DOI: 10.18632/oncotarget.20119] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
491 Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020;10:297-306. [PMID: 33312891 DOI: 10.5500/wjt.v10.i11.297] [Reference Citation Analysis]
492 Du J, Mao Y, Liu M, Tie Y, Huang H, Zhao J, Xiang Z, Luo D. Dose age affect the efficacy of molecular targeted agents in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:102413-9. [PMID: 29254256 DOI: 10.18632/oncotarget.22061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
493 Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. Clin Drug Investig 2015;35:751-9. [PMID: 26446004 DOI: 10.1007/s40261-015-0333-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
494 Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38:614-622. [PMID: 28344323 DOI: 10.1038/aps.2017.5] [Cited by in Crossref: 209] [Cited by in F6Publishing: 200] [Article Influence: 52.3] [Reference Citation Analysis]
495 Gao F, Huang C, Zhang Y, Sun R, Zhang Y, Wang H, Zhang S. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa. Cancer Biol Ther 2016;17:595-8. [PMID: 27030639 DOI: 10.1080/15384047.2016.1167290] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
496 Bhatia R, Ravulapati S, Befeler A, Dombrowski J, Gadani S, Poddar N. Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management-Single-Center Experience. J Gastrointest Cancer 2017;48:321-5. [PMID: 28891006 DOI: 10.1007/s12029-017-9998-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
497 Zhang Y, Li D, Jiang Q, Cao S, Sun H, Chai Y, Li X, Ren T, Yang R, Feng F, Li BA, Zhao Q. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis 2018;9:743. [PMID: 29970890 DOI: 10.1038/s41419-018-0804-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 54] [Article Influence: 14.0] [Reference Citation Analysis]
498 Li X, Zhang D, Guan S, Ye W, Liu L, Lou L. Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. Oncotarget 2017;8:93179-85. [PMID: 29190987 DOI: 10.18632/oncotarget.21452] [Reference Citation Analysis]
499 Yu WC, Zhang KZ, Chen SG, Liu WF. Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study. Medicine (Baltimore). 2018;97:e9704. [PMID: 29505026 DOI: 10.1097/md.0000000000009704] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
500 Feliu J, Sastre J, Maurel J, Isla D. Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. Clin Transl Oncol 2011;13:536-44. [PMID: 21821487 DOI: 10.1007/s12094-011-0694-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
501 Nguyen TTH, Nguyen VH, Nguyen VH, Nguyen TL, Le VQ. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam. Cancer Control. 2019;26:1073274819865269. [PMID: 31364390 DOI: 10.1177/1073274819865269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
502 Xia YQ, Hua RJ, Juan C, Zhong ZH, Tao CS, Fang R, Lin H, Rui G, Yong C. SIRT6 Depletion Sensitizes Human Hepatoma Cells to Chemotherapeutics by Downregulating MDR1 Expression. Front Pharmacol 2018;9:194. [PMID: 29563873 DOI: 10.3389/fphar.2018.00194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
503 Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World J Gastroenterol 2021;27:2415-33. [PMID: 34040331 DOI: 10.3748/wjg.v27.i19.2415] [Reference Citation Analysis]
504 Ye M, Xu M, Ding M, Ji C, Ji J, Ji F, Wei W, Yang S, Zhou B. Gender associated effects of the ethanolic extracts of Chinese propolis on the hepatic transcriptome in ethanol-treated mice. Iran J Basic Med Sci 2019;22:1211-7. [PMID: 31998465 DOI: 10.22038/ijbms.2019.37348.8886] [Reference Citation Analysis]
505 Zhang W. Sorafenib in adjuvant setting: call for precise and personalized therapy. Transl Gastroenterol Hepatol 2016;1:13. [PMID: 28138580 DOI: 10.21037/tgh.2016.03.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
506 Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 2012;14:564-74. [PMID: 22855137 DOI: 10.1007/s12094-012-0842-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
507 Kempinska K, Malik B, Borkin D, Klossowski S, Shukla S, Miao H, Wang J, Cierpicki T, Grembecka J. Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma. Mol Cancer Ther 2018;17:26-38. [PMID: 29142068 DOI: 10.1158/1535-7163.MCT-17-0580] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
508 Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, Poon RT. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011;16:1270-1279. [PMID: 21885876 DOI: 10.1634/theoncologist.2011-0105] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
509 Kudo M. Biomarkers and Personalized Sorafenib Therapy. Liver Cancer 2014;3:399-404. [PMID: 26280001 DOI: 10.1159/000343870] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
510 Fang Q, Chen H. Development of a Novel Autophagy-Related Prognostic Signature and Nomogram for Hepatocellular Carcinoma. Front Oncol 2020;10:591356. [PMID: 33392087 DOI: 10.3389/fonc.2020.591356] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
511 Hatooka M, Kawaoka T, Aikata H, Inagaki Y, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Awai K, Masaki K, Waki K, Kohno H, Kohno H, Moriya T, Nagaoki Y, Tamura T, Amano H, Katamura Y, Chayama K. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC Cancer 2018;18:633. [PMID: 29866075 DOI: 10.1186/s12885-018-4519-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
512 Siddharth S, Muniraj N, Saxena NK, Sharma D. Concomitant Inhibition of Cytoprotective Autophagy Augments the Efficacy of Withaferin A in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E453. [PMID: 30934990 DOI: 10.3390/cancers11040453] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
513 Ha Y, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Park SR, Ryu MH, Ryoo BY, Kang YK, Kim KM. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma. Oncotarget 2016;7:74303-13. [PMID: 27494871 DOI: 10.18632/oncotarget.11030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
514 Li X, Guo W, Guo L, Lau WY, Ge N, Wang K, Cheng S. Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? a propensity score matching study. Oncotarget 2018;9:24537-47. [PMID: 29849959 DOI: 10.18632/oncotarget.25224] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
515 Murata S, Mine T, Sugihara F, Yasui D, Yamaguchi H, Ueda T, Onozawa S, Kumita S. Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol. 2014;20:13453-13465. [PMID: 25309076 DOI: 10.3748/wjg.v20.i37.13453] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
516 Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surg Nutr 2018;7:487-9. [PMID: 30652096 DOI: 10.21037/hbsn.2018.10.06] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 7.7] [Reference Citation Analysis]
517 Sun H, Zhu MS, Wu WR, Shi XD, Xu LB. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. World J Hepatol 2014;6:830-5. [PMID: 25544869 DOI: 10.4254/wjh.v6.i12.830] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
518 Sakabe T, Tsuchiya H, Kanki K, Azumi J, Gonda K, Mizuta Y, Yamada D, Wada H, Shomori K, Nagano H, Shiota G. Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance. PLoS One 2013;8:e56197. [PMID: 23457527 DOI: 10.1371/journal.pone.0056197] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
519 Chen J, White SB, Harris KR, Li W, Yap JW, Kim DH, Lewandowski RJ, Shea LD, Larson AC. Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model. Biomaterials 2015;61:299-306. [PMID: 26022791 DOI: 10.1016/j.biomaterials.2015.05.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
520 Tahmasebi Birgani M, Carloni V. Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy. Int J Mol Sci 2017;18:E405. [PMID: 28216578 DOI: 10.3390/ijms18020405] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 18.0] [Reference Citation Analysis]
521 Huan HB, Lau WY, Xia F, Ma KS, Bie P. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World J Gastroenterol 2014;20:14505-9. [PMID: 25339839 DOI: 10.3748/wjg.v20.i39.14505] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
522 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-855. [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627] [Cited by in Crossref: 790] [Cited by in F6Publishing: 755] [Article Influence: 112.9] [Reference Citation Analysis]
523 Xie ZB, Ma L, Wang XB, Bai T, Ye JZ, Zhong JH, Li LQ. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. Tumour Biol. 2014;35:8451-8459. [PMID: 25038916 DOI: 10.1007/s13277-014-2340-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
524 Liu L, Zhang C, Zhao Y, Qi X, Chen H, Bai W, He C, Guo W, Yin Z, Fan D, Han G. Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients. Biomed Res Int. 2014;2014:194278. [PMID: 24800212 DOI: 10.1155/2014/194278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
525 Yu JI, Yoon SM, Park HC, Kim JH, Kim TH, Park JW, Seong J, Lee IJ, Jang HS, Kay CS. Multicenter validation study of a prognostic index for portal vein tumor thrombosis in hepatocellular carcinoma. Cancer Res Treat. 2014;46:348-357. [PMID: 25036573 DOI: 10.4143/crt.2013.142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
526 Karbownik A, Stachowiak A, Urjasz H, Sobańska K, Szczecińska A, Grabowski T, Stanisławiak-Rudowicz J, Wolc A, Grześkowiak E, Szałek E. The oxidation and hypoglycaemic effect of sorafenib in streptozotocin-induced diabetic rats. Pharmacol Rep 2020;72:254-9. [PMID: 32016844 DOI: 10.1007/s43440-019-00021-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
527 Wang K, Guo WX, Chen MS, Mao YL, Sun BC, Shi J, Zhang YJ, Meng Y, Yang YF, Cong WM, Wu MC, Lau WY, Cheng SQ. Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. Medicine (Baltimore). 2016;95:e3015. [PMID: 26986115 DOI: 10.1097/md.0000000000003015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 8.2] [Reference Citation Analysis]
528 Jia AY, Popovic A, Mohan AA, Zorzi J, Griffith P, Kim AK, Anders RA, Burkhart RA, Lafaro K, Georgiades C, Azad NS, Liddell RP, Baretti M, Kamel IR, Narang A, Yarchoan M, Meyer J. Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control 2021;28:10732748211009945. [PMID: 33882707 DOI: 10.1177/10732748211009945] [Reference Citation Analysis]
529 Huang WK, Yang SF, You LN, Liu M, Liu DY, Gu P, Fan XW. Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. Contemp Oncol (Pozn) 2016;20:468-74. [PMID: 28239285 DOI: 10.5114/wo.2016.65607] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
530 Marasco G, Poggioli F, Colecchia A, Cabibbo G, Pelizzaro F, Giannini EG, Marinelli S, Rapaccini GL, Caturelli E, Di Marco M, Biasini E, Marra F, Morisco F, Foschi FG, Zoli M, Gasbarrini A, Svegliati Baroni G, Masotto A, Sacco R, Raimondo G, Azzaroli F, Mega A, Vidili G, Brunetto MR, Nardone G, Alemanni LV, Dajti E, Ravaioli F, Festi D, Trevisani F, Italian Liver Cancer Ita Li Ca Group OBOT. A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. Cancers (Basel) 2021;13:2677. [PMID: 34072309 DOI: 10.3390/cancers13112677] [Reference Citation Analysis]
531 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett 2017;14:1637-47. [PMID: 28789390 DOI: 10.3892/ol.2017.6287] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
532 Peixoto RD, Renouf DJ, Gill S, Cheung WY, Lim HJ. Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. J Gastrointest Oncol 2014;5:259-64. [PMID: 25083298 DOI: 10.3978/j.issn.2078-6891.2014.036] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
533 Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 2012;7:e49717. [PMID: 23284624 DOI: 10.1371/journal.pone.0049717] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
534 Tsai TH, Chen YJ, Wang LY, Hsieh CH. Impact of Local Liver Irradiation Concurrent Versus Sequential with Lenvatinib on Pharmacokinetics and Biodistribution. Cancers (Basel) 2021;13:1598. [PMID: 33808407 DOI: 10.3390/cancers13071598] [Reference Citation Analysis]
535 Okusaka T, Ueno H, Ikeda M, Takezako Y, Morizane C. Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma. Cancer Sci. 2012;103:1524-1530. [PMID: 22587457 DOI: 10.1111/j.1349-7006.2012.02334] [Reference Citation Analysis]
536 Borzio M, Dionigi E, Rossini A, Toldi A, Francica G, Fornari F, Salmi A, Farinati F, Vicari S, Marignani M. Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an italian in-field experience. Dig Dis Sci. 2015;60:1465-1473. [PMID: 25399329 DOI: 10.1007/s10620-014-3427-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
537 Ting CT, Cheng YY, Tsai TH. Preclinical Pharmacokinetic Interaction and Histopathological Analyses of Hedyotis diffusa on Sorafenib in Rats. ACS Omega 2021;6:3060-7. [PMID: 33553923 DOI: 10.1021/acsomega.0c05461] [Reference Citation Analysis]
538 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Eguchi S, Yamashita T, Kudo M. Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer 2019;8:403-11. [PMID: 31768348 DOI: 10.1159/000495944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
539 Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, Chen Q, Zhang T, Shen J, Liu M, Huang J. Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. Cancers (Basel) 2018;10:E516. [PMID: 30558224 DOI: 10.3390/cancers10120516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
540 Liao J, Jin H, Li S, Xu L, Peng Z, Wei G, Long J, Guo Y, Kuang M, Zhou Q, Peng S. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:454. [PMID: 31694662 DOI: 10.1186/s13046-019-1419-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
541 Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018;379:54-63. [PMID: 29972759 DOI: 10.1056/NEJMoa1717002] [Cited by in Crossref: 703] [Cited by in F6Publishing: 391] [Article Influence: 234.3] [Reference Citation Analysis]
542 Wang M, Wu M, Yang T. The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma. EBioMedicine 2019;40:11-2. [PMID: 30651221 DOI: 10.1016/j.ebiom.2019.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
543 Zhang Y, Gao X, Zhu Y, Kadel D, Sun H, Chen J, Luo Q, Sun H, Yang L, Yang J, Sheng Y, Zheng Y, Zhu K, Dong Q, Qin L. The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 2018;37:93. [PMID: 29712569 DOI: 10.1186/s13046-018-0750-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
544 Sueangoen N, Tantiwetrueangdet A, Panvichian R. HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant. Cell Biosci 2020;10:41. [PMID: 32190291 DOI: 10.1186/s13578-020-00407-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
545 Kan X, Liang B, Zhou G, Xiong B, Pan F, Ren Y, Cao Y, Wang J, Yang F, Zheng C. Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol 2020;10:970. [PMID: 32733791 DOI: 10.3389/fonc.2020.00970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
546 Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AX. Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. Liver Cancer 2017;6:360-74. [PMID: 29234639 DOI: 10.1159/000481315] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
547 Kong Y, Sun L, Hou Z, Zhang Y, Chen P, Cui Y, Zhu X, Song T, Li Q, Li H, Zhang T, Qin L. Apatinib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget. 2017;8:105596-105605. [PMID: 29285275 DOI: 10.18632/oncotarget.22337] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
548 Chai ZT, Zhang XP, Shao M, Ao JY, Chen ZH, Zhang F, Hu YR, Zhong CQ, Lin JH, Fang KP, Wu MC, Lau WY, Cheng SQ. Impact of splenomegaly and splenectomy on prognosis in hepatocellular carcinoma with portal vein tumor thrombus treated with hepatectomy. Ann Transl Med 2021;9:247. [PMID: 33708874 DOI: 10.21037/atm-20-2229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
549 Li XD, Wang Z, Wang XR, Shao D, Zhang X, Li L, Ge MF, Chang ZM, Dong WF. Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition. Int J Nanomedicine 2019;14:3967-82. [PMID: 31239666 DOI: 10.2147/IJN.S206044] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
550 Ye S, Zhao XY, Hu XG, Li T, Xu QR, Yang HM, Huang DS, Yang L. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. Oncol Rep 2017;37:2215-26. [PMID: 28350084 DOI: 10.3892/or.2017.5494] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
551 Demirkan S, Gündüz Ö, Devrim T. Sorafenib-asssociated hand-foot syndrome treated with topical calcipotriol. JAAD Case Rep 2017;3:354-7. [PMID: 28761920 DOI: 10.1016/j.jdcr.2017.03.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
552 Kerbel RS. Reappraising antiangiogenic therapy for breast cancer. Breast 2011;20 Suppl 3:S56-60. [PMID: 22015294 DOI: 10.1016/S0960-9776(11)70295-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
553 He X, Qu F, Zhou F, Zhou X, Chen Y, Guo X, Li J, Huang Q, Yang Y, Lyu Z, Zhang H, Xing J. High leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patients. Oncotarget 2016;7:22834-45. [PMID: 26985767 DOI: 10.18632/oncotarget.8071] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
554 Kudo M. Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma. Liver Cancer. 2018;7:123-133. [PMID: 29888203 DOI: 10.1159/000488542] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
555 Kudo M. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer 2019;8:299-311. [PMID: 31768341 DOI: 10.1159/000502905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
556 Zhao H, Guo Y, Li S, Han R, Ying J, Zhu H, Wang Y, Yin L, Han Y, Sun L, Wang Z, Lin Q, Bi X, Jiao Y, Jia H, Zhao J, Huang Z, Li Z, Zhou J, Song W, Meng K, Cai J. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget 2015;6:31927-43. [PMID: 26376676 DOI: 10.18632/oncotarget.5578] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
557 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 133] [Article Influence: 36.5] [Reference Citation Analysis]
558 Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. Genes Dis 2020;7:359-69. [PMID: 32884990 DOI: 10.1016/j.gendis.2020.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
559 Ikeda M, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Watanabe K, Umemoto K, Okusaka T. Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future. Diseases 2015;3:360-81. [PMID: 28943630 DOI: 10.3390/diseases3040360] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
560 Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Lee WJ, Kim DY, Kim CM. Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther Onkol 2014;190:882-90. [PMID: 24638270 DOI: 10.1007/s00066-014-0643-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
561 Rimassa L, Porta C, Borbath I, Daniele B, Finn RS, Raoul JL, Schwartz LH, He AR, Trojan J, Peck-Radosavljevic M, Abbadessa G, Goldberg T, Santoro A, Bruix J. Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. Hepat Oncol 2014;1:181-8. [PMID: 30190953 DOI: 10.2217/hep.14.3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
562 Yamamoto K, Shinomiya K, Ioroi T, Hirata S, Harada K, Suno M, Nishioka T, Kume M, Makimoto H, Nakagawa T, Hirano T, Bito T, Nishigori C, Miyake H, Fujisawa M, Hirai M. Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients. Targ Oncol 2016;11:93-9. [DOI: 10.1007/s11523-015-0382-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
563 Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014;20:4115-27. [PMID: 24764650 DOI: 10.3748/wjg.v20.i15.4115] [Cited by in CrossRef: 231] [Cited by in F6Publishing: 203] [Article Influence: 38.5] [Reference Citation Analysis]
564 Roviello G, Casadei-Gardini A, Nobili S, Mini E, Fancelli S. Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. J Oncol 2020;2020:8024124. [PMID: 32655640 DOI: 10.1155/2020/8024124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
565 Lin S, Hoffmann K, Xiao Z, Jin N, Galli U, Mohr E, Büchler MW, Schemmer P. MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. Cancer Cell Int 2013;13:3. [PMID: 23320839 DOI: 10.1186/1475-2867-13-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
566 Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, Zhong J, Shang C, Chen Y. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway. Oncol Res 2017;25:1543-53. [PMID: 28276313 DOI: 10.3727/096504017X14886444100783] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
567 Ling S, Li J, Shan Q, Dai H, Lu D, Wen X, Song P, Xie H, Zhou L, Liu J, Xu X, Zheng S. USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. Mol Oncol 2017;11:682-95. [PMID: 28417539 DOI: 10.1002/1878-0261.12067] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
568 Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 2020;5:87. [PMID: 32532960 DOI: 10.1038/s41392-020-0187-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 35.0] [Reference Citation Analysis]
569 Zhong J, Dong X, Xiu P, Wang F, Liu J, Wei H, Xu Z, Liu F, Li T, Li J. Blocking autophagy enhances meloxicam lethality to hepatocellular carcinoma by promotion of endoplasmic reticulum stress. Cell Prolif 2015;48:691-704. [PMID: 26481188 DOI: 10.1111/cpr.12221] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
570 He AR, Goldenberg AS. Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap Adv Gastroenterol 2013;6:447-58. [PMID: 24179481 DOI: 10.1177/1756283X13498540] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
571 Chiba T, Suzuki E, Saito T, Ogasawara S, Ooka Y, Tawada A, Iwama A, Yokosuka O. Biological features and biomarkers in hepatocellular carcinoma. World J Hepatol. 2015;7:2020-2028. [PMID: 26261691 DOI: 10.4254/wjh.v7.i16.2020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
572 Rim CH, Kim CY, Yang DS, Yoon WS. The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies. Cancer Manag Res. 2018;10:3305-3315. [PMID: 30233246 DOI: 10.2147/cmar.s175703] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
573 Delos Santos S, Udayakumar S, Nguyen A, Ko YJ, Berry S, Doherty M, Chan KKW. A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma. Curr Oncol 2020;27:300-6. [PMID: 33380861 DOI: 10.3747/co.27.6583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
574 Dipasquale A, Marinello A, Santoro A. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario. J Hepatocell Carcinoma 2021;8:241-51. [PMID: 33884259 DOI: 10.2147/JHC.S270532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
575 Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol 2015;3:169-81. [PMID: 26623263 DOI: 10.14218/JCTH.2015.00012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
576 Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58. [PMID: 20628345 DOI: 10.1038/nrgastro.2010.100] [Cited by in Crossref: 810] [Cited by in F6Publishing: 758] [Article Influence: 73.6] [Reference Citation Analysis]
577 Jeon JS, Kwon S, Ban K, Kwon Hong Y, Ahn C, Sung JS, Choi I. Regulation of the Intracellular ROS Level Is Critical for the Antiproliferative Effect of Quercetin in the Hepatocellular Carcinoma Cell Line HepG2. Nutr Cancer 2019;71:861-9. [PMID: 30661409 DOI: 10.1080/01635581.2018.1559929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
578 Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 2014;111:101-6. [PMID: 24622679 DOI: 10.3238/arztebl.2014.0101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 30] [Article Influence: 0.8] [Reference Citation Analysis]
579 Lee JS, Kim MY, Park ER, Shen YN, Jeon JY, Cho EH, Park SH, Han CJ, Choi DW, Jang JJ, Suh KS, Hong J, Kim SB, Lee KH. TMEM165, a Golgi transmembrane protein, is a novel marker for hepatocellular carcinoma and its depletion impairs invasion activity. Oncol Rep 2018;40:1297-306. [PMID: 30015898 DOI: 10.3892/or.2018.6565] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
580 Li Z, Ye L, Liu J, Lian D, Li X. Sorafenib-Loaded Nanoparticles Based on Biodegradable Dendritic Polymers for Enhanced Therapy of Hepatocellular Carcinoma. Int J Nanomedicine 2020;15:1469-80. [PMID: 32184599 DOI: 10.2147/IJN.S237335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
581 Wada Y, Takami Y, Ryu T, Ureshino H, Imamura H, Sasaki S, Saitsu H. A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression. Case Rep Oncol 2020;13:379-84. [PMID: 32355493 DOI: 10.1159/000506331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
582 Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Curr Oncol Rep 2016;18:9. [PMID: 26769114 DOI: 10.1007/s11912-015-0494-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
583 Yanai S, Nakamura S, Ooho A, Nakamura S, Esaki M, Azuma K, Kitazono T, Matsumoto T. Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment. Clin J Gastroenterol. 2015;8:116-119. [PMID: 25832768 DOI: 10.1007/s12328-015-0566-y] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
584 Ranieri G, Marech I, Lorusso V, Goffredo V, Paradiso A, Ribatti D, Gadaleta CD. Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol. 2014;20:486-497. [PMID: 24574717 DOI: 10.3748/wjg.v20.i2.486] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
585 Yang W, Wang D, Huang L, Chen Y, Wen S, Hong Q, Kang D. Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach. Asian Pac J Cancer Prev 2018;19:2043-55. [PMID: 30139041 DOI: 10.22034/APJCP.2018.19.8.2043] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
586 Hendrickson PG, Olson M, Luetkens T, Weston S, Han T, Atanackovic D, Fine GC. The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.Oncoimmunology. 2020;9:1673129. [PMID: 32002284 DOI: 10.1080/2162402X.2019.1673129] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
587 Ogasawara S, Chiba T, Ooka Y, Suzuki E, Kanogawa N, Saito T, Motoyama T, Tawada A, Kanai F, Yokosuka O. Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. Invest New Drugs. 2016;34:255-260. [PMID: 26769245 DOI: 10.1007/s10637-016-0323-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
588 Li Y, Chen G, Han Z, Cheng H, Qiao L, Li Y. IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells. Onco Targets Ther 2020;13:9721-30. [PMID: 33061451 DOI: 10.2147/OTT.S262089] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
589 Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF. Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clin Cancer Res 2017;23:4633-41. [PMID: 28465443 DOI: 10.1158/1078-0432.CCR-16-3171] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 10.8] [Reference Citation Analysis]
590 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol. 2013;19:7316-7326. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
591 Zheng J, Shao G, Luo J. Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib. Clin Transl Oncol. 2014;16:1012-1017. [PMID: 24894839 DOI: 10.1007/s12094-014-1189-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
592 Kang MK, Park JG, Lee HJ. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore). 2018;97:e0611. [PMID: 29703062 DOI: 10.1097/md.0000000000010611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
593 Wu J, Zhu AX. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol. 2011;4:30. [PMID: 21729319 DOI: 10.1186/1756-8722-4-8730] [Reference Citation Analysis]
594 Zhu Q, Zhang X, Li J, Huang L, Yan J, Xu F, Yan Y. Arterial blood supply of hepatocellular carcinoma is associated with efficacy of sorafenib therapy. Ann Transl Med 2015;3:285. [PMID: 26697445 DOI: 10.3978/j.issn.2305-5839.2015.10.24] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
595 Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang N, An X, Yu J, Li H, Ren X. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. 2014;34:194-203. [PMID: 24337625 DOI: 10.1007/s10875-013-9976-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
596 Ferrín G, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL, de la Mata M. Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepat Med 2015;7:1-10. [PMID: 25926760 DOI: 10.2147/HMER.S50161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
597 You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. J Hematol Oncol 2016;9:20. [PMID: 26957312 DOI: 10.1186/s13045-016-0253-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
598 Yutani S, Shirahama T, Muroya D, Matsueda S, Yamaguchi R, Morita M, Shichijo S, Yamada A, Sasada T, Itoh K. Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies. Cancer Sci. 2017;108:1732-1738. [PMID: 28622427 DOI: 10.1111/cas.13301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
599 Qi X, Guo X. Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies. Prz Gastroenterol. 2015;10:142-147. [PMID: 26516379 DOI: 10.5114/pg.2015.52470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
600 Wang QS, Shi LL, Sun F, Zhang YF, Chen RW, Yang SL, Hu JL. High Expression of ANXA2 Pseudogene ANXA2P2 Promotes an Aggressive Phenotype in Hepatocellular Carcinoma. Dis Markers 2019;2019:9267046. [PMID: 30881525 DOI: 10.1155/2019/9267046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
601 Lee JS, Kim JH, Park YY, Mills GB. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011;43:205-11. [PMID: 22247704 DOI: 10.4143/crt.2011.43.4.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
602 Ko SF, Yip HK, Zhen YY, Lee CC, Lee CC, Huang CC, Ng SH, Lin JW. Adipose-Derived Mesenchymal Stem Cell Exosomes Suppress Hepatocellular Carcinoma Growth in a Rat Model: Apparent Diffusion Coefficient, Natural Killer T-Cell Responses, and Histopathological Features. Stem Cells Int. 2015;2015:853506. [PMID: 26345219 DOI: 10.1155/2015/853506] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
603 Diaz-Beveridge R, Bruixola G, Lorente D, Caballero J, Rodrigo E, Segura Á, Akhoundova D, Giménez A, Aparicio J. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. Clin Transl Oncol 2018;20:322-9. [PMID: 28801777 DOI: 10.1007/s12094-017-1720-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
604 Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645. [PMID: 28899349 DOI: 10.1186/s12885-017-3545-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
605 He M, Li Q, Zou R, Shen J, Fang W, Tan G, Zhou Y, Wu X, Xu L, Wei W, Le Y, Zhou Z, Zhao M, Guo Y, Guo R, Chen M, Shi M. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019;5:953-960. [PMID: 31070690 DOI: 10.1001/jamaoncol.2019.0250] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 62.0] [Reference Citation Analysis]
606 Salimon M, Prieux-Klotz C, Tougeron D, Hautefeuille V, Caulet M, Gournay J, Matysiak-Budnik T, Bennouna J, Tiako Meyo M, Lecomte T, Zaanan A, Touchefeu Y. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer. 2018;118:325-330. [PMID: 29169182 DOI: 10.1038/bjc.2017.413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
607 Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol. 2014;20:4141-4150. [PMID: 24764652 DOI: 10.3748/wjg.v20.i15.4141] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 55] [Article Influence: 9.8] [Reference Citation Analysis]
608 Tang Q, Huang W, Liang J, Xue J. Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study. Front Oncol 2021;11:646410. [PMID: 34307128 DOI: 10.3389/fonc.2021.646410] [Reference Citation Analysis]
609 Hsu HT, Chi CW. Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:127-35. [PMID: 27508182 DOI: 10.2147/JHC.S48512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
610 Tuxun T, Apaer S, Yao G, Wang Z, Gu S, Zeng Q, Aizezijiang A, Wu J, Anweier N, Zhao J, Li T. Atrial reconstruction, distal gastrectomy with Ante-situm liver resection and autotransplantation for hepatocellular carcinoma with atrial tumor thrombus: A case report. Medicine (Baltimore) 2021;100:e25780. [PMID: 34106611 DOI: 10.1097/MD.0000000000025780] [Reference Citation Analysis]
611 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 295] [Article Influence: 31.0] [Reference Citation Analysis]
612 Borhani AA, Catania R, Velichko YS, Hectors S, Taouli B, Lewis S. Radiomics of hepatocellular carcinoma: promising roles in patient selection, prediction, and assessment of treatment response. Abdom Radiol (NY) 2021;46:3674-85. [PMID: 33891149 DOI: 10.1007/s00261-021-03085-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
613 Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:238-51. [PMID: 31900465 DOI: 10.1038/s41575-019-0240-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 29.0] [Reference Citation Analysis]
614 Xie A, Hanif S, Ouyang J, Tang Z, Kong N, Kim NY, Qi B, Patel D, Shi B, Tao W. Stimuli-responsive prodrug-based cancer nanomedicine. EBioMedicine 2020;56:102821. [PMID: 32505922 DOI: 10.1016/j.ebiom.2020.102821] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 26.0] [Reference Citation Analysis]
615 Kim SE, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. Korean J Hepatol. 2011;17:113-119. [PMID: 21757982 DOI: 10.3350/kjhep.2011.17.2.113] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
616 Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 2013;12:611-29. [PMID: 23903221 DOI: 10.1038/nrd4088] [Cited by in Crossref: 237] [Cited by in F6Publishing: 219] [Article Influence: 29.6] [Reference Citation Analysis]
617 Jiang N, Li H, Sun Y, Zeng J, Yang F, Kantawong F, Wu J. Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma. Front Pharmacol 2021;12:618522. [PMID: 33746755 DOI: 10.3389/fphar.2021.618522] [Reference Citation Analysis]
618 Hu H, Duan Z, Long X, Hertzanu Y, Tong X, Xu X, Shi H, Liu S, Yang Z. Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study. PLoS One 2015;10:e0117168. [PMID: 25689846 DOI: 10.1371/journal.pone.0117168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
619 Bi Y, Jiang H, Wang P, Song B, Wang H, Kong X, Li Z. Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager. Oncotarget 2017;8:52866-76. [PMID: 28881778 DOI: 10.18632/oncotarget.17905] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
620 Samson A, Bentham MJ, Scott K, Nuovo G, Bloy A, Appleton E, Adair RA, Dave R, Peckham-Cooper A, Toogood G, Nagamori S, Coffey M, Vile R, Harrington K, Selby P, Errington-Mais F, Melcher A, Griffin S. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut 2018;67:562-73. [PMID: 27902444 DOI: 10.1136/gutjnl-2016-312009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
621 Kusano H, Ogasawara S, Akiba J, Nakayama M, Ueda K, Yano H. Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo. Int J Oncol 2013;42:1897-903. [PMID: 23588838 DOI: 10.3892/ijo.2013.1904] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
622 Boige V, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, Pignon JP, Vimond N, Bouvet-Forteau N, De Baere T, Ducreux M, Farace F. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17:1063-1072. [PMID: 22707516 DOI: 10.1634/theoncologist.2011-0465] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
623 Chan WM, McFadden G. Oncolytic Poxviruses. Annu Rev Virol 2014;1:119-41. [PMID: 25839047 DOI: 10.1146/annurev-virology-031413-085442] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
624 Yang Y, Jin M, Dai Y, Shan W, Chen S, Cai R, Yang H, Tang L, Li L. Involvement and Targeted Intervention of Mortalin-Regulated Proteome Phosphorylated-Modification in Hepatocellular Carcinoma. Front Oncol 2021;11:687871. [PMID: 34395254 DOI: 10.3389/fonc.2021.687871] [Reference Citation Analysis]
625 Liu KC, Hao YH, Lv WF, Jia WD, Ji CS, Zhou CZ, Cheng DL, Xu SB, Gao ZG, Su MX, Shi CS. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. Drug Des Devel Ther 2020;14:3461-8. [PMID: 32904650 DOI: 10.2147/DDDT.S248850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
626 Zhou TY, Zhuang LH, Hu Y, Zhou YL, Lin WK, Wang DD, Wan ZQ, Chang LL, Chen Y, Ying MD, Chen ZB, Ye S, Lou JS, He QJ, Zhu H, Yang B. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. Sci Rep. 2016;6:30483. [PMID: 27476430 DOI: 10.1038/srep30483] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
627 Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2015;21:3843-3849. [PMID: 25852268 DOI: 10.3748/wjg.v21.i13.3843] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
628 Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clin Gastroenterol Hepatol 2021;19:1520-30. [PMID: 32652308 DOI: 10.1016/j.cgh.2020.06.072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
629 Hayano K, Lee SH, Sahani DV. Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian J Radiol Imaging 2015;25:121-8. [PMID: 25969635 DOI: 10.4103/0971-3026.155835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
630 Yen YH, Cheng YF, Wang JH, Lin CC, Chen YY, Yong CC, Liu YW, Cheng JY, Chen CH, Hu TH. Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. PLoS One 2020;15:e0230005. [PMID: 32163475 DOI: 10.1371/journal.pone.0230005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
631 Chen MH, Yang WL, Lin KT, Liu CH, Liu YW, Huang KW, Chang PM, Lai JM, Hsu CN, Chao KM, Kao CY, Huang CY. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. PLoS One. 2011;6:e27186. [PMID: 22087264 DOI: 10.1371/journal.pone.0027186] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
632 Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. J Exp Clin Cancer Res. 2016;35:159. [PMID: 27716356 DOI: 10.1186/s13046-016-0430-z] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 15.6] [Reference Citation Analysis]
633 Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, Huang SK, Colquhoun S, Hoon DS. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget. 2015;6:3211-3224. [PMID: 25633810 DOI: 10.18632/oncotarget.3085] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 20.2] [Reference Citation Analysis]
634 Paik EK, Kim MS, Choi CW, Jang WI, Lee SH, Choi SH, Kim KB, Lee DH. Dosimetric comparison of volumetric modulated arc therapy with robotic stereotactic radiation therapy in hepatocellular carcinoma. Radiat Oncol J. 2015;33:233-241. [PMID: 26484307 DOI: 10.3857/roj.2015.33.3.233] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
635 Kosaka Y, Kawaoka T, Ogawa Y, Amioka K, Naruto K, Yoshikawa Y, Ando Y, Suehiro Y, Yamaoka K, Fujii Y, Uchikawa S, Ono A, Yamauchi M, Imamura M, Chosa K, Awai K, Nagata Y, Chayama K, Aikata H. Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study. Clin J Gastroenterol 2021. [PMID: 34291386 DOI: 10.1007/s12328-021-01481-9] [Reference Citation Analysis]
636 Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, Inoue Y, Uchiyama K. Surgical treatment of extrahepatic recurrence of hepatocellular carcinoma. Langenbecks Arch Surg. 2014;399:1057-1064. [PMID: 25030500 DOI: 10.1007/s00423-014-1230-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
637 Han C, Ye S, Hu C, Shen L, Qin Q, Bai Y, Yang S, Bai C, Zang A, Jiao S, Bai L. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). Front Oncol 2021;11:684867. [PMID: 34327136 DOI: 10.3389/fonc.2021.684867] [Reference Citation Analysis]
638 Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer 2021;10:275-84. [PMID: 34239813 DOI: 10.1159/000515553] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
639 Wang H, Wu L, Wang H. Development and verification of a personalized immune prognostic feature in breast cancer. Exp Biol Med (Maywood) 2020;245:1242-53. [PMID: 32600059 DOI: 10.1177/1535370220936964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
640 Chan SL. Drug development for hepatocellular carcinoma: knowing the past helps to understand the future. Oncologist. 2014;19:1115-1117. [PMID: 25223461 DOI: 10.1634/theoncologist.2014-0304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
641 Chen JY, Chen YJ, Yen CJ, Chen WS, Huang WC. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget 2016;7:473-89. [PMID: 26595522 DOI: 10.18632/oncotarget.6337] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
642 Chow AK, Ng L, Lam CS, Wong SK, Wan TM, Cheng NS, Yau TC, Poon RT, Pang RW. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One. 2013;8:e78675. [PMID: 24244338 DOI: 10.1371/journal.pone.0078675] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 8.4] [Reference Citation Analysis]
643 Pievsky D, Pyrsopoulos N. Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date. J Hepatocell Carcinoma. 2016;3:69-76. [PMID: 27896243 DOI: 10.2147/jhc.s106072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
644 Kudo M. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers (Basel). 2018;10. [PMID: 30380773 DOI: 10.3390/cancers10110412] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 26.0] [Reference Citation Analysis]
645 Shimamura Y, Abe K, Maeda T, Matsui T, Ishiguro A, Takizawa H. Association Between Renal Adverse Effects and Mortality in Patients With Hepatocellular Carcinoma Treated With Lenvatinib. In Vivo 2021;35:1647-53. [PMID: 33910848 DOI: 10.21873/invivo.12423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
646 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis. J Cancer 2017;8:378-87. [PMID: 28261338 DOI: 10.7150/jca.16786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
647 Zhang X, Zhang P, An L, Sun N, Peng L, Tang W, Ma D, Chen J. Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis. Acta Pharm Sin B 2020;10:1397-413. [PMID: 32963939 DOI: 10.1016/j.apsb.2020.06.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
648 Zhao Y, Duran R, Chapiro J, Sohn JH, Sahu S, Fleckenstein F, Smolka S, Pawlik TM, Schernthaner R, Zhao L, Lee H, He S, Lin M, Geschwind JF. Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. J Gastrointest Surg 2016;20:2002-9. [PMID: 27714643 DOI: 10.1007/s11605-016-3285-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
649 Qin S, Cheng Y, Liang J, Shen L, Bai Y, Li J, Fan J, Liang L, Zhang Y, Wu G. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist. 2014;19:1169-1178. [PMID: 25223462 DOI: 10.1634/theoncologist.2014-0190] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
650 Mross K, Richly H, Fischer R, Scharr D, Büchert M, Stern A, Gille H, Audoly LP, Scheulen ME. First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS One 2013;8:e83232. [PMID: 24349470 DOI: 10.1371/journal.pone.0083232] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
651 Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. Br J Cancer 2018;118:1162-8. [PMID: 29563636 DOI: 10.1038/s41416-018-0051-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
652 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z, Lou M, Lv J. Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med. 2012;3:171-180. [PMID: 22969864 DOI: 10.3892/etm.2011.398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
653 Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Yokosuka O. Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma? Int J Clin Oncol 2014;19:1029-36. [PMID: 24519322 DOI: 10.1007/s10147-014-0668-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
654 Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer 2019;7:333. [PMID: 31783782 DOI: 10.1186/s40425-019-0824-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 19.5] [Reference Citation Analysis]
655 Kielbassa K, Vegna S, Ramirez C, Akkari L. Understanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers. Front Immunol 2019;10:2215. [PMID: 31611871 DOI: 10.3389/fimmu.2019.02215] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
656 Tong H, Wei B, Chen S, Xie YM, Zhang MG, Zhang LH, Huang ZY, Tang CW. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget 2017;8:48303-12. [PMID: 28430638 DOI: 10.18632/oncotarget.15684] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
657 Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM, Nair S. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol. 2012;35:329-333. [PMID: 21422991 DOI: 10.1097/coc.0b013e3182118cdf] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
658 Qin SK, Li Q, Ming Xu J, Liang J, Cheng Y, Fan Y, Jiang J, Ye H, Tao H, Li L, Zheng L, Wei Z, Li S, Meng K, Ye B, Sun Y. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. Cancer Sci. 2020;111:4218-4231. [PMID: 32889778 DOI: 10.1111/cas.14641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
659 Terazawa T, Kondo S, Hosoi H, Morizane C, Shimizu S, Mitsunaga S, Ikeda M, Ueno H, Okusaka T. Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial. BMC Cancer 2014;14:301. [PMID: 24779747 DOI: 10.1186/1471-2407-14-301] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
660 Patel A, Sun W. Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future. Curr Treat Options Oncol. 2014;15:380-394. [PMID: 24838298 DOI: 10.1007/s11864-014-0291-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
661 Maehara O, Sato F, Natsuizaka M, Asano A, Kubota Y, Itoh J, Tsunematsu S, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Chuma M, Nakagawa K, Ohnishi S, Komatsu Y, Whelan KA, Nakagawa H, Takeda H, Sakamoto N. A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. Cancer Biol Ther 2015;16:1453-61. [PMID: 26176896 DOI: 10.1080/15384047.2015.1070992] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
662 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 239] [Article Influence: 43.3] [Reference Citation Analysis]
663 Ikeda M, Ohkawa S, Okusaka T, Mitsunaga S, Kobayashi S, Morizane C, Suzuki I, Yamamoto S, Furuse J. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci. 2014;105:455-462. [PMID: 24521523 DOI: 10.1111/cas.12368] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
664 Shingina A, Hashim AM, Haque M, Suen M, Yoshida EM, Gill S, Donnellan F, Weiss AA. In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can J Gastroenterol 2013;27:393-6. [PMID: 23862169 DOI: 10.1155/2013/170546] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
665 Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 2016;3:1-7. [PMID: 27574586 DOI: 10.2147/JHC.S62261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
666 Meng W, Li X, Bai Z, Li Y, Yuan J, Liu T, Yan J, Zhou W, Zhu K, Zhang H, Li Y. Silencing alpha-fetoprotein inhibits VEGF and MMP-2/9 production in human hepatocellular carcinoma cell. PLoS One 2014;9:e90660. [PMID: 24587407 DOI: 10.1371/journal.pone.0090660] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
667 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: